<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="creatine" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">creatine</book-part-id>
      <title-group>
        <title>Creatine Deficiency Syndromes</title>
        <alt-title alt-title-type="alt-title">Synonym: Cerebral Creatine Deficiency Syndromes</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mercimek-Mahmutoglu</surname>
            <given-names>Saadet</given-names>
          </name>
          <degrees>MD, PhD, FCCMG</degrees>
          <aff>Assistant Professor, Division of Clinical and Metabolic Genetics<break/>Department of Pediatrics<break/>University of Toronto<break/>The Hospital for Sick Children<break/>Toronto, Ontario, Canada</aff>
          <email>saadet.mahmutoglu@sickkids.ca</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Salomons</surname>
            <given-names>Gajja S</given-names>
          </name>
          <degrees>PhD</degrees>
          <aff>Professor, Department of Clinical Chemistry<break/>Metabolic Unit<break/>VU University Medical Center<break/>Amsterdam, The Netherlands</aff>
          <email>g.salomons@vumc.nl</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>15</day>
          <month>1</month>
          <year>2009</year>
        </date>
        <date date-type="updated">
          <day>10</day>
          <month>12</month>
          <year>2015</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="cranio-md" document-type="chapter">Craniometaphyseal Dysplasia, Autosomal Dominant</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="cf" document-type="chapter">Cystic Fibrosis and Congenital Absence of the Vas Deferens</related-object>
      <abstract id="creatine.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>The cerebral creatine deficiency syndromes (CCDS), inborn errors of creatine metabolism, include the two creatine biosynthesis disorders, guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency, and the creatine transporter (CRTR) deficiency. Intellectual disability and seizures are common to all three CCDS. The majority of individuals with GAMT deficiency have a behavior disorder that can include autistic behaviors and self-mutilation; about 40% have movement disorder. Onset is between ages three months and three years. Only 14 individuals with AGAT deficiency have been reported. The phenotype of CRTR deficiency in affected males ranges from mild intellectual disability and speech delay to severe intellectual disability, seizures, movement disorder and behavior disorder; age at diagnosis ranges from two to 66 years. Clinical phenotype of females heterozygous for CRTR deficiency ranges from asymptomatic to severe phenotype resembling male phenotype.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Cerebral creatine deficiency in brain MR spectroscopy (<sup>1</sup>H-MRS) is the characteristic hallmark of all CCDS. Diagnosis of CCDS relies on: measurement of guanidinoacetate (GAA), creatine, and creatinine in urine and plasma; and molecular genetic testing of the three genes involved, <italic toggle="yes">GAMT</italic>, <italic toggle="yes">GATM</italic>, and <italic toggle="yes">SLC6A8</italic>. If molecular genetic test results are inconclusive, GAMT enzyme activity (in cultured fibroblast or lymphoblasts), GATM enzyme activity (in lymphoblasts), or creatine uptake in cultured fibroblasts can be assessed.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> GAMT deficiency and AGAT deficiency are treated with oral creatine monohydrate to replenish cerebral creatine levels. Treatment of GAMT deficiency requires supplementation of ornithine and dietary restriction of arginine or protein. In males with CRTR deficiency creatine supplementation alone does not improve clinical outcome and does not result in replenished cerebral creatine levels; likewise, high-dose L-arginine and L-glycine supplementation so far has not consistently improve clinical or biochemical outcome in males although some have been reported to have increased muscle mass and improved motor and personal social IQ skills. One female with intractable epilepsy responded to high-dose L-arginine and L-glycine supplementation with cessation of seizures.</p>
          <p><italic toggle="yes">Prevention of primary manifestations</italic>: Early treatment at the asymptomatic stage of the disease in individuals with GAMT and AGAT deficiencies appears to be beneficial: treatment in newborn sibs of individuals with AGAT or GAMT deficiency prevented disease manifestations.</p>
          <p><italic toggle="yes">Surveillance</italic>: In those treated with creatine monohydrate, routine measurement of renal function to detect possible creatine-associated nephropathy is warranted.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Early diagnosis of neonates at risk for GAMT deficiency, AGAT deficiency, and CRTR deficiency by biochemical or molecular genetic testing allows for early diagnosis and treatment of the defects in creatine metabolism.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>GAMT deficiency and AGAT deficiency are inherited in an autosomal recessive manner. At conception, each sib of an individual with GAMT deficiency or AGAT deficiency has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. CRTR deficiency is inherited in an X-linked manner. Mothers who are carriers have a 50% chance of transmitting the pathogenic variant in each pregnancy; sons who inherit the pathogenic variant will be affected; daughters who inherit the pathogenic variant will be heterozygous and may have learning and behavior problems. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible for all three defects in creatine metabolism if the pathogenic variants in the family are known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="creatine.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="creatine.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_creatine.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">Creatine Deficiency Syndromes: Included Phenotypes</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_creatine.Tc_1_1_1_1" valign="top" align="left" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Guanidinoacetate methyltransferase (GAMT) deficiency</p>
                    </list-item>
                    <list-item>
                      <p>L-arginine:glycine amidinotransferase (AGAT) deficiency</p>
                    </list-item>
                    <list-item>
                      <p>Creatine transporter (CRTR) deficiency</p>
                    </list-item>
                  </list>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="creatine.Diagnosis">
        <title>Diagnosis</title>
        <p>The cerebral creatine deficiency syndromes (CCDS) are inborn errors of creatine metabolism that include [<xref ref-type="bibr" rid="creatine.REF.stockleripsiroglu.2012">Stockler-Ipsiroglu et al 2012</xref>]:</p>
        <list list-type="bullet">
          <list-item>
            <p>Two creatine biosynthesis defects (both inherited in an autosomal recessive manner):</p>
            <list list-type="bullet">
              <list-item>
                <p>Guanidinoacetate methyltransferase (GAMT) deficiency</p>
              </list-item>
              <list-item>
                <p>L-arginine:glycine amidinotransferase (AGAT) deficiency</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>One creatine transporter defect (inherited in an X-linked manner):</p>
            <list list-type="bullet">
              <list-item>
                <p>Creatine transporter (CRTR) deficiency</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <sec id="creatine.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Cerebral creatine deficiency syndromes (CCDS) <bold>should be suspected</bold> in:</p>
          <list list-type="bullet">
            <list-item>
              <p>A young child with global developmental delay, hypotonia, seizures, and movement disorder;</p>
            </list-item>
            <list-item>
              <p>An older child with intellectual disability, epilepsy, movement disorder, and behavior problems.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="table" rid="creatine.T.clinical_features_of_gamt_aga">Table 1</xref>.</p>
          <table-wrap id="creatine.T.clinical_features_of_gamt_aga" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Clinical Features of GAMT, AGAT, and CRTR Deficiency</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_1">Deficiency</th>
                  <th id="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_2"># of Affected Persons</th>
                  <th id="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_3" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_3">ID</th>
                  <th id="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_4" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Epilepsy</th>
                  <th id="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_5" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Movement Disorder&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_6" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_6">Behavior Problems</th>
                </tr>
                <tr>
                  <th headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_4" id="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Frequency</th>
                  <th headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_4" id="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Drug Resistance</th>
                  <th headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_5" id="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Frequency</th>
                  <th headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_5" id="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Severity</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">GAMT</td>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">110</td>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Mild to severe</td>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_4 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">69/80 (86%)&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_4 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">46%&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_5 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">30/80 (37.5%)&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_5 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">Mild to severe&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">Hyperactivity, autism spectrum disorder, aggressive behavior, self-injurious behavior</td>
                </tr>
                <tr>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">AGAT</td>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">14</td>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Mild to moderate</td>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_4 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">2/14 (14%)</td>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_4 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">None</td>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_5 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">None</td>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_5 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">None</td>
                </tr>
                <tr>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">CRTR</td>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;160&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Mild to severe</td>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_4 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">59/101 (60%) males&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_4 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">3/59 (5%)&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_5 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">41/101 (40%)&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_5 hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">Mild to severe&#x000a0;<sup>4</sup></td>
                  <td headers="hd_h_creatine.T.clinical_features_of_gamt_aga_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">86/101 (85%) attention deficit hyperactivity, autism spectrum disorder&#x000a0;<sup>3</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>ID = intellectual disability</p>
              </fn>
              <fn id="creatine.TF.1.1">
                <label>1. </label>
                <p>Dystonia, chorea, choreoathetosis, ataxia</p>
              </fn>
              <fn id="creatine.TF.1.2">
                <label>2. </label>
                <p>Based on the 80 patients reported by <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al [2006]</xref>, <xref ref-type="bibr" rid="creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al [2014]</xref>, and <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al [2014a]</xref></p>
              </fn>
              <fn id="creatine.TF.1.3">
                <label>3. </label>
                <p>The authors are aware of more than 160 patients; however, the clinical characteristics have only been described for ~101 males from 85 families. The most recent international registry paper to review these data is <xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013a.463">van de Kamp et al [2013a]</xref>.</p>
              </fn>
              <fn id="creatine.TF.1.4">
                <label>4. </label>
                <p>101 males reported by <xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013b.155">van de Kamp et al [2013b]</xref> had movement disorder including ataxia (29%) and dystonia or athetosis (11%).</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <sec id="creatine.Screening_Tests">
            <title>Screening Tests</title>
            <p><bold>Levels of guanidinoacetate (GAA), creatine, and creatinine</bold> are measured in urine (<xref ref-type="table" rid="creatine.T.urinary_metabolites_by_ccds_d">Table 2</xref>), plasma (<xref ref-type="table" rid="creatine.T.plasma_concentration_of_metab">Table 3</xref>), and cerebrospinal fluid (CSF) (<xref ref-type="table" rid="creatine.T.csf_concentration_of_metaboli">Table 4</xref>) [<xref ref-type="bibr" rid="creatine.REF.almeida.2004.214">Almeida et al 2004</xref>, <xref ref-type="bibr" rid="creatine.REF.cognat.2004.1459">Cognat et al 2004</xref>, <xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2014.715">van de Kamp et al 2014</xref>, <xref ref-type="bibr" rid="creatine.REF.m_rkrid.2015.760">M&#x000f8;rkrid et al 2015</xref>].</p>
            <table-wrap id="creatine.T.urinary_metabolites_by_ccds_d" orientation="portrait" position="anchor">
              <label>Table 2. </label>
              <caption>
                <p>Urinary Metabolites by CCDS Disorder</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_1" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Deficiency</th>
                    <th id="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">GAA&#x000a0;<sup>1</sup> Concentration</th>
                    <th id="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Creatine Concentration</th>
                    <th id="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Creatine/Creatinine Ratio</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_1" valign="middle" colspan="2" align="left" scope="row" rowspan="1">
                      <bold>GAMT</bold>
                    </td>
                    <td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Elevated&#x000a0;<sup>2</sup></td>
                    <td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Low to low normal&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Low normal</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_1" valign="middle" colspan="2" align="left" scope="row" rowspan="1">
                      <bold>AGAT</bold>
                    </td>
                    <td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Low to low normal&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Low normal&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Low normal</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <bold>CRTR</bold>
                    </td>
                    <td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">
                      <bold>Males</bold>
                    </td>
                    <td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Normal&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Normal to elevated</td>
                    <td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Elevated&#x000a0;<sup>6</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                      <bold>Females</bold>
                    </td>
                    <td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                    <td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Normal to elevated</td>
                    <td headers="hd_h_creatine.T.urinary_metabolites_by_ccds_d_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Normal to mildly elevated</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="creatine.TF.2.1">
                  <label>1. </label>
                  <p>Guanidinoacetate</p>
                </fn>
                <fn id="creatine.TF.2.2">
                  <label>2. </label>
                  <p>Pathognomonic finding</p>
                </fn>
                <fn id="creatine.TF.2.3">
                  <label>3. </label>
                  <p><xref ref-type="bibr" rid="creatine.REF.battini.2002.326">Battini et al [2002]</xref>, <xref ref-type="bibr" rid="creatine.REF.stockleripsiroglu.2012">Stockler-Ipsiroglu et al [2012]</xref></p>
                </fn>
                <fn id="creatine.TF.2.4">
                  <label>4. </label>
                  <p><xref ref-type="bibr" rid="creatine.REF.almeida.2004.214">Almeida et al [2004]</xref>, <xref ref-type="bibr" rid="creatine.REF.cognat.2004.1459">Cognat et al [2004]</xref></p>
                </fn>
                <fn id="creatine.TF.2.5">
                  <label>5. </label>
                  <p>If GAA is presented as guanidinoacetate mmol/mol creatinine, the values may appear slightly increased because of the generally lower creatinine values in males with CRTR deficiency.</p>
                </fn>
                <fn id="creatine.TF.2.6">
                  <label>6. </label>
                  <p>Diagnostic finding [<xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</xref>, <xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2014.715">van de Kamp et al 2014</xref>]</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <table-wrap id="creatine.T.plasma_concentration_of_metab" orientation="portrait" position="anchor">
              <label>Table 3. </label>
              <caption>
                <p>Plasma Concentration of Metabolites by CCDS Disorder</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_1" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Deficiency</th>
                    <th id="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">GAA&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Creatine</th>
                    <th id="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Creatinine</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_1" valign="middle" colspan="2" align="left" scope="row" rowspan="1">
                      <bold>GAMT</bold>
                    </td>
                    <td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Elevated&#x000a0;<sup>2</sup></td>
                    <td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Low</td>
                    <td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_4" rowspan="4" valign="middle" align="left" colspan="1">Low to normal&#x000a0;<sup>4</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_1" valign="middle" colspan="2" align="left" scope="row" rowspan="1">
                      <bold>AGAT</bold>
                    </td>
                    <td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Low to low normal&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Low&#x000a0;<sup>3</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <bold>CRTR</bold>
                    </td>
                    <td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">
                      <bold>Males</bold>
                    </td>
                    <td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">Normal</td>
                    <td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Normal&#x000a0;<sup>3</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                      <bold>Females</bold>
                    </td>
                    <td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_3" valign="middle" colspan="1" align="left" rowspan="1">Normal</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_1" valign="middle" colspan="2" align="left" scope="row" rowspan="1">
                      <bold>Normal</bold>
                    </td>
                    <td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">See age-related reference range&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                    <td headers="hd_h_creatine.T.plasma_concentration_of_metab_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="creatine.TF.3.1">
                  <label>1. </label>
                  <p>Guanidinoacetate</p>
                </fn>
                <fn id="creatine.TF.3.2">
                  <label>2. </label>
                  <p>
                    <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al [2006]</xref>
                  </p>
                </fn>
                <fn id="creatine.TF.3.3">
                  <label>3. </label>
                  <p><xref ref-type="bibr" rid="creatine.REF.almeida.2004.214">Almeida et al [2004]</xref>, <xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2015.141">van de Kamp et al [2015]</xref></p>
                </fn>
                <fn id="creatine.TF.3.4">
                  <label>4. </label>
                  <p>Determination of plasma creatinine concentration alone cannot identify a CCDS.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <table-wrap id="creatine.T.csf_concentration_of_metaboli" orientation="portrait" position="anchor">
              <label>Table 4. </label>
              <caption>
                <p>CSF Concentration of Metabolites by CCDS Disorder</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_1" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Deficiency</th>
                    <th id="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">GAA&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Creatine</th>
                    <th id="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Creatinine</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_1" valign="middle" colspan="2" align="left" scope="row" rowspan="1">
                      <bold>GAMT</bold>
                    </td>
                    <td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Elevated&#x000a0;<sup>2</sup></td>
                    <td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Low</td>
                    <td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Low</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_1" valign="middle" colspan="2" align="left" scope="row" rowspan="1">
                      <bold>AGAT</bold>
                    </td>
                    <td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">No data</td>
                    <td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">No data</td>
                    <td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">No data</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <bold>CRTR</bold>
                    </td>
                    <td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">
                      <bold>Males</bold>
                    </td>
                    <td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Normal to mildly elevated&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Normal to mildly elevated&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Low</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                      <bold>Females</bold>
                    </td>
                    <td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">No data</td>
                    <td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">No data</td>
                    <td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">No data</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_1" valign="middle" colspan="2" align="left" scope="row" rowspan="1">
                      <bold>Normal</bold>
                    </td>
                    <td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">See age-related reference range&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                    <td headers="hd_h_creatine.T.csf_concentration_of_metaboli_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="creatine.TF.4.1">
                  <label>1. </label>
                  <p>Guanidinoacetate</p>
                </fn>
                <fn id="creatine.TF.4.2">
                  <label>2. </label>
                  <p>
                    <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al [2006]</xref>
                  </p>
                </fn>
                <fn id="creatine.TF.4.3">
                  <label>3. </label>
                  <p>
                    <xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013b.155">van de Kamp et al [2013b]</xref>
                  </p>
                </fn>
                <fn id="creatine.TF.4.4">
                  <label>4. </label>
                  <p><xref ref-type="bibr" rid="creatine.REF.almeida.2004.214">Almeida et al [2004]</xref>, <xref ref-type="bibr" rid="creatine.REF.cognat.2004.1459">Cognat et al [2004]</xref></p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Brain imaging for in vivo assessment of brain creatine levels.</bold> Proton magnetic resonance spectroscopy (<sup>1</sup>H-MRS) reveals almost complete depletion of the cerebral creatine pool in all individuals with GAMT deficiency and AGAT deficiency and in males with CRTR deficiency. Partial depletion or even normal levels of the cerebral creatine pool are observed in female carriers with X-linked CRTR deficiency [<xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2011.264">van de Kamp et al 2011</xref>].</p>
            <p>Note: Complete lack of creatine in the presence of a normal choline and N-acetyl aspartate (NAA) levels in <sup>1</sup>H-MRS is unique to CCDS [<xref ref-type="bibr" rid="creatine.REF.st_ckler.1996.914">St&#x000f6;ckler et al 1996</xref>].</p>
          </sec>
        </sec>
        <sec id="creatine.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of CCDS <bold>is established</bold> in a proband with identification of biallelic pathogenic variants in <italic toggle="yes">GAMT or GATM</italic> or a hemizygous pathogenic variant (in males) of <italic toggle="yes">SLC6A8</italic> on molecular genetic testing (see <xref ref-type="table" rid="creatine.T.summary_of_molecular_genetic">Table 5</xref>) using the following algorithm for guidance.</p>
          <p><bold>The diagnostic testing algorithm</bold> for an individual with the listed clinical features and/or reduced creatine levels on brain <sup>1</sup>H-MRS (see <xref ref-type="fig" rid="creatine.F1">Figure 1</xref>) is:</p>
          <list list-type="bullet">
            <list-item>
              <p>Measurement of guanidinoacetate (GAA), creatine, and creatinine in urine (<xref ref-type="table" rid="creatine.T.urinary_metabolites_by_ccds_d">Table 2</xref>) and plasma (<xref ref-type="table" rid="creatine.T.plasma_concentration_of_metab">Table 3</xref>).</p>
              <list list-type="bullet">
                <list-item>
                  <p>If GAA concentration in urine is high, molecular genetic testing of <italic toggle="yes">GAMT</italic></p>
                </list-item>
                <list-item>
                  <p>If GAA concentration in urine is low and plasma concentration of GAA is low, molecular genetic testing of <italic toggle="yes">GATM</italic></p>
                </list-item>
                <list-item>
                  <p>If creatine/creatinine ratio in urine is high and GAA concentration in the urine is normal or slightly increased, molecular genetic testing of <italic toggle="yes">SLC6A8</italic>. Note: Diagnosis of heterozygous female probands requires molecular genetic testing of <italic toggle="yes">SLC6A8</italic> because they may have a normal creatine-to-creatinine ratio in urine and normal creatine content on brain <sup>1</sup>H-MRS [<xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2011.264">van de Kamp et al 2011</xref>].</p>
                </list-item>
                <list-item>
                  <p>If molecular genetic test results are inconclusive (i.e., if sequence variants of unknown significance are identified), GAMT enzyme activity (in cultured fibroblast or lymphoblasts), AGAT enzyme activity (in lymphoblasts), or creatine uptake in cultured fibroblasts can be assessed [<xref ref-type="bibr" rid="creatine.REF.item.2001.1127">Item et al 2001</xref>, <xref ref-type="bibr" rid="creatine.REF.verhoeven.2003.803">Verhoeven et al 2003</xref>, <xref ref-type="bibr" rid="creatine.REF.verhoeven.2004.441">Verhoeven et al 2004</xref>].</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>Note: Methods for testing GAMT enzyme activity (in cultured fibroblast or lymphoblasts), AGAT enzyme activity (in lymphoblasts), or creatine uptake in cultured fibroblasts have been reported and may be helpful in the interpretation of variants of unknown significance [<xref ref-type="bibr" rid="creatine.REF.rosenberg.2007.890">Rosenberg et al 2007</xref>, <xref ref-type="bibr" rid="creatine.REF.betsalel.2012.596">Betsalel et al 2012</xref>, <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2012a.433">Mercimek-Mahmutoglu et al 2012a</xref>, <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</xref>, <xref ref-type="bibr" rid="creatine.REF.desroches.2015.2163">Desroches et al 2015</xref>]. See <xref ref-type="sec" rid="creatine.Molecular_Genetics">Molecular Genetics</xref> for details.</p>
          <p>Molecular genetic testing approaches can include <bold>serial single-gene testing</bold>, use of a <bold>multi-gene panel</bold>, and <bold>more comprehensive</bold>
<bold>genomic testing</bold>.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold><italic toggle="yes">GAMT</italic>, <italic toggle="yes">GATM</italic>, and <italic toggle="yes">SLC6A8</italic> testing</bold> is advised if biochemical features (e.g. creatine deficiency in brain <sup>1</sup>H-MRS) are suggestive of GAMT, AGAT, or CRTR deficiency.</p>
            </list-item>
            <list-item>
              <p><bold>Serial single gene testing</bold> is advised in the case of specific abnormalities in metabolites of creatine metabolism in body fluids (<xref ref-type="table" rid="creatine.T.urinary_metabolites_by_ccds_d">Tables 2-4</xref>). Sequence analysis of the gene of interest is performed first, followed by gene-targeted deletion/duplication analysis and/or mRNA analysis if only one or no pathogenic variant is found.</p>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">GAMT</italic>, <italic toggle="yes">GATM, SLC6A8,</italic> and other genes of interest (see <xref ref-type="sec" rid="creatine.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered in patients with global developmental delay, intellectual disability, and/or epilepsy and/or movement disorder who did not undergo biochemical investigations for CCDS. Note: The genes included and sensitivity of multi-gene panels vary by laboratory and over time.</p>
            </list-item>
            <list-item>
              <p><bold>More comprehensive genomic testing</bold> (when available) including exome sequencing, genome sequencing, and mitochondrial sequencing may be considered if serial single-gene testing (and/or use of a multi-gene panel) fails to confirm a diagnosis in an individual with features of CCDS. For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
            </list-item>
          </list>
          <table-wrap id="creatine.T.summary_of_molecular_genetic" orientation="portrait" position="anchor">
            <label>Table 5. </label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in CCDS</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_creatine.T.summary_of_molecular_genetic_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_creatine.T.summary_of_molecular_genetic_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_creatine.T.summary_of_molecular_genetic_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_creatine.T.summary_of_molecular_genetic_1_1_1_2">Proportion of CCDS Attributed to Pathogenic Variants in This Gene</th>
                  <th id="hd_h_creatine.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detected by Test Method&#x000a0;<sup>3</sup></th>
                </tr>
                <tr>
                  <th headers="hd_h_creatine.T.summary_of_molecular_genetic_1_1_1_3" id="hd_h_creatine.T.summary_of_molecular_genetic_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Sequence analysis&#x000a0;<sup>4</sup></th>
                  <th headers="hd_h_creatine.T.summary_of_molecular_genetic_1_1_1_3" id="hd_h_creatine.T.summary_of_molecular_genetic_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_creatine.T.summary_of_molecular_genetic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">GAMT</italic>
                  </td>
                  <td headers="hd_h_creatine.T.summary_of_molecular_genetic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">39%&#x000a0;<sup>6</sup></td>
                  <td headers="hd_h_creatine.T.summary_of_molecular_genetic_1_1_1_3 hd_h_creatine.T.summary_of_molecular_genetic_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">~100%&#x000a0;<sup>6</sup></td>
                  <td headers="hd_h_creatine.T.summary_of_molecular_genetic_1_1_1_3 hd_h_creatine.T.summary_of_molecular_genetic_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>7</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_creatine.T.summary_of_molecular_genetic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">GATM</italic>
                  </td>
                  <td headers="hd_h_creatine.T.summary_of_molecular_genetic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">5%&#x000a0;<sup>8</sup></td>
                  <td headers="hd_h_creatine.T.summary_of_molecular_genetic_1_1_1_3 hd_h_creatine.T.summary_of_molecular_genetic_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">~100%&#x000a0;<sup>8</sup></td>
                  <td headers="hd_h_creatine.T.summary_of_molecular_genetic_1_1_1_3 hd_h_creatine.T.summary_of_molecular_genetic_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>7</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_creatine.T.summary_of_molecular_genetic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">SLC6A8</italic>
                  </td>
                  <td headers="hd_h_creatine.T.summary_of_molecular_genetic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">56%&#x000a0;<sup>9</sup></td>
                  <td headers="hd_h_creatine.T.summary_of_molecular_genetic_1_1_1_3 hd_h_creatine.T.summary_of_molecular_genetic_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">~95%&#x000a0;<sup>9,&#x000a0;10</sup></td>
                  <td headers="hd_h_creatine.T.summary_of_molecular_genetic_1_1_1_3 hd_h_creatine.T.summary_of_molecular_genetic_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">~5%&#x000a0;<sup>11</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="creatine.TF.5.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="creatine" object-id="creatine.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="creatine.TF.5.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="creatine.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="creatine.TF.5.3">
                <label>3. </label>
                <p>In individuals with biochemical and/or enzymatic diagnosis of a specific CCDS</p>
              </fn>
              <fn id="creatine.TF.5.4">
                <label>4. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="creatine.TF.5.5">
                <label>5. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used can include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="creatine.TF.5.6">
                <label>6. </label>
                <p><xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al [2006]</xref>, <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al [2014a]</xref>, <xref ref-type="bibr" rid="creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al [2014]</xref></p>
              </fn>
              <fn id="creatine.TF.5.7">
                <label>7. </label>
                <p>No data on detection rate of gene-targeted deletion/duplication analysis are available.</p>
              </fn>
              <fn id="creatine.TF.5.8">
                <label>8. </label>
                <p><xref ref-type="bibr" rid="creatine.REF.item.2001.1127">Item et al [2001]</xref>, Battini et l [2002], <xref ref-type="bibr" rid="creatine.REF.battini.2006.828">Battini et al [2006]</xref>, <xref ref-type="bibr" rid="creatine.REF.edvardson.2010.228">Edvardson et al [2010]</xref>, <xref ref-type="bibr" rid="creatine.REF.verma.2010.186">Verma [2010]</xref>, <xref ref-type="bibr" rid="creatine.REF.ndika.2012.48">Ndika et al [2012]</xref>, <xref ref-type="bibr" rid="creatine.REF.comeaux.2013.260">Comeaux et al [2013]</xref>, <xref ref-type="bibr" rid="creatine.REF.nouioua.2013.670">Nouioua et al [2013]</xref></p>
              </fn>
              <fn id="creatine.TF.5.9">
                <label>9. </label>
                <p>
                  <xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013a.463">van de Kamp et al [2013a]</xref>
                </p>
              </fn>
              <fn id="creatine.TF.5.10">
                <label>10. </label>
                <p>Lack of amplification by PCR prior to sequence analysis can suggest a putative (multi)exon or whole-gene deletion on the X chromosome in affected males; confirmation requires additional testing by gene-targeted deletion/duplication analysis.</p>
              </fn>
              <fn id="creatine.TF.5.11">
                <label>11. </label>
                <p><xref ref-type="bibr" rid="creatine.REF.anselm.2006.214">Anselm et al [2006]</xref>, <xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2015.141">van de Kamp et al [2015]</xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.lovd.nl/SLC6A8">Leiden Open Variation Database</ext-link></p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="creatine.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="creatine.Clinical_Description">
          <title>Clinical Description</title>
          <p>Intellectual disability and seizures are common to all three creatine deficiency syndromes. Intellectual disability is associated with expressive speech delay and behavior disorder [<xref ref-type="bibr" rid="creatine.REF.stockleripsiroglu.2012">Stockler-Ipsiroglu et al 2012</xref>].</p>
          <sec id="creatine.GAMT_Deficiency">
            <title>GAMT Deficiency</title>
            <p>Approximately 110 affected individuals have been published either as single case reports or small groups of cases [<xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</xref>, <xref ref-type="bibr" rid="creatine.REF.verbruggen.2007.921">Verbruggen et al 2007</xref>, <xref ref-type="bibr" rid="creatine.REF.vodopiutz.2007.773">Vodopiutz et al 2007</xref>, <xref ref-type="bibr" rid="creatine.REF.dhar.2009.38">Dhar et al 2009</xref>, <xref ref-type="bibr" rid="creatine.REF.engelke.2009.538">Engelke et al 2009</xref>, <xref ref-type="bibr" rid="creatine.REF.o_rourke.2009.404">O&#x02019;Rourke et al 2009</xref>, <xref ref-type="bibr" rid="creatine.REF.sempere.2009a.745">Sempere et al 2009a</xref>, <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2010b.s101">Mercimek-Mahmutoglu et al 2010b</xref>, <xref ref-type="bibr" rid="creatine.REF.cheillan.2012.96">Cheillan et al 2012</xref>, <xref ref-type="bibr" rid="creatine.REF.nasrallah.2012.427">Nasrallah et al 2012</xref>, <xref ref-type="bibr" rid="creatine.REF.comeaux.2013.260">Comeaux et al 2013</xref>, <xref ref-type="bibr" rid="creatine.REF.elgharbawy.2013.215">El-Gharbawy et al 2013</xref>, <xref ref-type="bibr" rid="creatine.REF.viau.2013.255">Viau et al 2013</xref>, <xref ref-type="bibr" rid="creatine.REF.akiyama.2014.65">Akiyama et al 2014</xref>, <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</xref>, <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2014b.133">Mercimek-Mahmutoglu et al 2014b</xref>, <xref ref-type="bibr" rid="creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</xref>].</p>
            <p>A review of 80 individuals with GAMT deficiency revealed that intellectual disability and epilepsy are the most consistent clinical features [<xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</xref>, <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</xref>, <xref ref-type="bibr" rid="creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</xref>]. About 60% of individuals with GAMT deficiency have a severe phenotype characterized by severe intellectual disability, intractable epilepsy, and movement disorder [<xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</xref>, <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</xref>, <xref ref-type="bibr" rid="creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</xref>].</p>
            <p><bold>Onset</bold> of the first clinical manifestations ranges from early infancy (age 3-6 months) to age three years.</p>
            <p><bold>Intellectual disability,</bold> the most consistent clinical manifestation, is present in all affected individuals. The severity of intellectual disability ranges from mild to severe. About 60% of individuals with GAMT deficiency have severe global developmental delay or intellectual disability [<xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</xref>, <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</xref>, <xref ref-type="bibr" rid="creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</xref>].</p>
            <p><bold>Language.</bold> Variable expressive language deficits were reported in two sibs with GAMT deficiency: the index case spoke fewer than ten words whereas her younger sister spoke in short sentences at age 13 years [<xref ref-type="bibr" rid="creatine.REF.o_rourke.2009.404">O&#x02019;Rourke et al 2009</xref>].</p>
            <p><bold>Seizures,</bold> the second most consistent manifestation in GAMT deficiency, are observed in about 78% of affected individuals. Seizure types include myoclonic, generalized tonic-clonic, partial complex, head nodding, and atonic seizures. Seizure severity ranges from occasional seizures to seizures which are non-responsive to various antiepileptic drugs [<xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</xref>, <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</xref>, <xref ref-type="bibr" rid="creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</xref>].</p>
            <p><bold>Movement disorders,</bold> observed in about 30% of individuals, are mainly chorea, athetosis, dystonia, or ataxia [<xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</xref>, <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</xref>, <xref ref-type="bibr" rid="creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</xref>]. Pathologic signal intensities in the basal ganglia in brain MRI are observed in individuals with or without a movement disorder [<xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</xref>, <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</xref>, <xref ref-type="bibr" rid="creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</xref>]. The onset is usually before age 12 years; however, recently a young woman with GAMT deficiency was reported to have onset of movement disorder (including ballistic and dystonic movements) at age 17 years [<xref ref-type="bibr" rid="creatine.REF.o_rourke.2009.404">O&#x02019;Rourke et al 2009</xref>].</p>
            <p><bold>A behavior disorder</bold> (e.g., hyperactivity, autism, or self-injurious behavior) is reported in about 77% of affected individuals [<xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</xref>, <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</xref>].</p>
          </sec>
          <sec id="creatine.AGAT_Deficiency">
            <title>AGAT Deficiency</title>
            <p>Fourteen individuals from seven families have been diagnosed with AGAT deficiency [<xref ref-type="bibr" rid="creatine.REF.item.2001.1127">Item et al 2001</xref>, <xref ref-type="bibr" rid="creatine.REF.battini.2002.326">Battini et al 2002</xref>, <xref ref-type="bibr" rid="creatine.REF.battini.2006.828">Battini et al 2006</xref>, <xref ref-type="bibr" rid="creatine.REF.edvardson.2010.228">Edvardson et al 2010</xref>, <xref ref-type="bibr" rid="creatine.REF.verma.2010.186">Verma 2010</xref>, <xref ref-type="bibr" rid="creatine.REF.ndika.2012.48">Ndika et al 2012</xref>, <xref ref-type="bibr" rid="creatine.REF.comeaux.2013.260">Comeaux et al 2013</xref>, <xref ref-type="bibr" rid="creatine.REF.nouioua.2013.670">Nouioua et al 2013</xref>].</p>
            <p><bold>Intellectual disability,</bold> the most consistent clinical manifestation, is present in all affected individuals. The severity of intellectual disability ranges from mild to moderate.</p>
            <p><bold>Seizures,</bold> observed in only 9% of affected individuals, were occasional and associated with fever.</p>
            <p><bold>Muscle weakness or hypotonia</bold> was observed in 67% of affected individuals [<xref ref-type="bibr" rid="creatine.REF.edvardson.2010.228">Edvardson et al 2010</xref>, <xref ref-type="bibr" rid="creatine.REF.verma.2010.186">Verma 2010</xref>, <xref ref-type="bibr" rid="creatine.REF.ndika.2012.48">Ndika et al 2012</xref>, <xref ref-type="bibr" rid="creatine.REF.nouioua.2013.670">Nouioua et al 2013</xref>].</p>
            <p><bold>Failure to thrive</bold> was reported in two sibs [<xref ref-type="bibr" rid="creatine.REF.edvardson.2010.228">Edvardson et al 2010</xref>].</p>
            <p><bold>A behavior disorder</bold> was present in 27% of affected individuals.</p>
            <p><bold>Movement disorders</bold> were not reported in any affected individuals.</p>
          </sec>
          <sec id="creatine.CRTR_Deficiency">
            <title>CRTR Deficiency</title>
            <p>
              <bold>Affected Males</bold>
            </p>
            <p>Since the first description of SLC6A8 deficiency by <xref ref-type="bibr" rid="creatine.REF.salomons.2001.1497">Salomons et al [2001]</xref>, 85 families comprising a total of 101 male individuals with an <italic toggle="yes">SLC6A8</italic> pathogenic variant have been reported in a single international registry study [<xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</xref>]. The phenotype ranges from mild intellectual disability and speech delay to severe intellectual disability, seizures, and behavior disorder that may become more marked during the course of the disease.</p>
            <p><bold>The age at diagnosis</bold> ranges from one to 66 years indicating that life expectancy can be normal. Now that the disorder is reasonably well described and diagnostic testing is more widely available, it is anticipated that diagnosis will mainly occur within the first three years of life.</p>
            <p><bold>Intellectual disability</bold> was present in all affected male individuals ranging from mild to severe: 85% of affected males had mild to moderate intellectual disability up to age four years; 75% of affected males older than age 18 years had severe intellectual disability [<xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</xref>]. One adult had progressive cognitive dysfunction [<xref ref-type="bibr" rid="creatine.REF.kleefstra.2005.379">Kleefstra et al 2005</xref>].</p>
            <p><bold>Speech-language disorder.</bold> Speech development was delayed in all affected males. First words were at a mean age of 3.1 years (age range: 9 months to 10 years). In affected males older than age ten years, 14% had no speech development, 55% were able to speak single words, and 31% were able to speak in sentences [<xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</xref>].</p>
            <p>A neuropsychological profile in four affected boys from two unrelated families from the Netherlands revealed a semantic-pragmatic language disorder (difficulty in understanding the meaning of words) with oral dyspraxia [<xref ref-type="bibr" rid="creatine.REF.mancini.2005.288">Mancini et al 2005</xref>].</p>
            <p><bold>Seizures</bold> were present in 59% of affected male individuals<bold>.</bold> The most common seizure type was generalized tonic-clonic and simple or complex partial seizures with or without secondary generalization. Absence and myoclonic seizures were rare. Age of seizure onset was between one and 21 years [<xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013b.155">van de Kamp et al 2013b</xref>]. Fewer than ten patients with intractable epilepsy have been reported [<xref ref-type="bibr" rid="creatine.REF.mancardi.2007.1211">Mancardi et al 2007</xref>, <xref ref-type="bibr" rid="creatine.REF.fons.2009.2168">Fons et al 2009</xref>, <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2010a.409">Mercimek-Mahmutoglu et al 2010a</xref>, <xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</xref>].</p>
            <p><bold>Movement disorder.</bold> Wide-based gait or ataxia and dystonia or athetosis were reported in 29% and 11% of affected males respectively [<xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</xref>].</p>
            <p><bold>Behavior disorder.</bold> Behavior disorder was reported in 85% of affected males. The most common behavior disorders were attention deficit and/or hyperactivity (55%) and autistic features (41%). Other behavior disorders reported in affected males include social anxiety or shyness (20%), stereotypic behavior (20%), impulsive behavior (27%), aggressive behavior (19%), self-injurious behavior (10%), and obsessive-compulsive behavior (8%) [<xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</xref>].</p>
            <p><bold>Other neurologic clinical features.</bold> Hypotonia was present in 40% of affected males. Spasticity was reported in 26% of affected males. Four individuals had mild (sensorial-neural) hearing loss. Nine affected males were reported with strabismus or bilateral abducens nerve palsy. Myopathic face, ptosis, joint laxity (likely secondary to the hypotonia), and decreased muscle bulk were also reported [<xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</xref>].</p>
            <p>
              <bold>Other non-neurologic clinical features</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Dysmorphic features</bold> including microcephaly, broad forehead, midface retrusion, high palate, short nose, prominent nasal bridge, ear differences (underfolded helices, large ears, and/or cupped ears), deeply set eyes, fifth finger clinodactyly, and slender body build were reported in 45% of affected males [<xref ref-type="bibr" rid="creatine.REF.anselm.2006.214">Anselm et al 2006</xref>, <xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</xref>, <xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013b.155">van de Kamp et al 2013b</xref>].</p>
              </list-item>
              <list-item>
                <p><bold>Gastrointestinal</bold>
<bold>findings</bold> including failure to thrive, vomiting, constipation, ileus likely secondary to constipation, hepatitis, gastric and duodenal ulcers, and hiatal hernia (which may or may not be related to CRTR deficiency) were reported in 35% of affected males [<xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</xref>].</p>
              </list-item>
              <list-item>
                <p><bold>Cardiac features.</bold> One boy with CRTR deficiency developed multiple premature ventricular contractions in his second year [<xref ref-type="bibr" rid="creatine.REF.anselm.2008.1642">Anselm et al 2008</xref>]. Two affected males with mild cardiomyopathy were reported [<xref ref-type="bibr" rid="creatine.REF.puusepp.2010.s5">Puusepp et al 2010</xref>]. One affected male had long QT syndrome [<xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</xref>].</p>
              </list-item>
              <list-item>
                <p><bold>Medical concerns in adulthood.</bold> Twenty-one of 101 affected males were adults (age &#x0003e;18 years). Adults affected with CRTR deficiency had intellectual disability ranging from moderate to severe [<xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013b.155">van de Kamp et al 2013b</xref>]. They presented with myopathic face, ptosis, external ophthalmoplegia, or parkinsonism. Chronic constipation leading to megacolon, ileus or bowel perforation, and/or gastric or duodenal ulcer disease have been reported in some adults [<xref ref-type="bibr" rid="creatine.REF.hahn.2002.1349">Hahn et al 2002</xref>, <xref ref-type="bibr" rid="creatine.REF.kleefstra.2005.379">Kleefstra et al 2005</xref>, <xref ref-type="bibr" rid="creatine.REF.sempere.2009b.s91">Sempere et al 2009b</xref>, <xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</xref>].</p>
              </list-item>
            </list>
            <p>
              <bold>Heterozygous Females</bold>
            </p>
            <p>Females heterozygous for their family-specific <italic toggle="yes">SLC6A8</italic> pathogenic variant are either asymptomatic or have mild intellectual disability [<xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2011.264">van de Kamp et al 2011</xref>]. There was no clinical correlation between skewed X-inactivation in favor of the pathogenic variant allele and severity of clinical phenotype. There was no significant statistical correlation between intellectual ability and cerebral creatine level on brain <sup>1</sup>H-MRS [<xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2011.264">van de Kamp et al 2011</xref>]. A female with mild intellectual disability, intractable epilepsy, and behavior problems (a phenotype similar to affected males) did not have evidence of skewed X-chromosome inactivation in peripheral blood cells; tissue-specific skewed X- chromosome inactivation in the brain could explain her severe neurologic findings [<xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2010a.409">Mercimek-Mahmutoglu et al 2010a</xref>].</p>
          </sec>
        </sec>
        <sec id="creatine.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>No genotype-phenotype correlations are known for any of the CCDS.</p>
          <p>Of note, the phenotypes of individuals homozygous for the two most common <italic toggle="yes">GAMT</italic> pathogenic variants (<xref ref-type="table" rid="creatine.T.selected_gamt_pathogenic_vari">c.59G&#x0003e;C</xref> and <xref ref-type="table" rid="creatine.T.selected_gamt_pathogenic_vari">c.327G&#x0003e;A</xref>) range from mild to severe.</p>
        </sec>
        <sec id="creatine.Prevalence">
          <title>Prevalence</title>
          <p><bold>GAMT deficiency.</bold> Approximately 110 individuals with GAMT deficiency have been diagnosed worldwide.</p>
          <p>The estimated incidence of GAMT deficiency in the general population ranges from 1:2,640,000 to 1:550,000 [<xref ref-type="bibr" rid="creatine.REF.desroches.2015.2163">Desroches et al 2015</xref>]. This is in agreement with information from pilot newborn screening programs for GAMT deficiency, which screened approximately 1,000,000 newborns; to date none of the newborns has a confirmed diagnosis of GAMT deficiency [<xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2012a.433">Mercimek-Mahmutoglu et al 2012a</xref>, <xref ref-type="bibr" rid="creatine.REF.pasquali.2014.231">Pasquali et al 2014</xref>, <xref ref-type="bibr" rid="creatine.REF.pitt.2014.303">Pitt et al 2014</xref>, <xref ref-type="bibr" rid="creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</xref>].</p>
          <p>In contrast, the estimated incidence of GAMT deficiency in the Utah newborn population was 1:114,072 [<xref ref-type="bibr" rid="creatine.REF.viau.2013.255">Viau et al 2013</xref>].</p>
          <p>Smaller studies of individuals with neurologic disease or severe intellectual disability found GAMT deficiency present in 0.094% and 1.1% respectively [<xref ref-type="bibr" rid="creatine.REF.caldeira_ara_jo.2005.122">Caldeira Ara&#x000fa;jo et al 2005</xref>, <xref ref-type="bibr" rid="creatine.REF.cheillan.2012.96">Cheillan et al 2012</xref>].</p>
          <p><bold>AGAT deficiency.</bold> No prevalence studies have been performed to date.</p>
          <p><bold>CRTR deficiency.</bold> CRTR deficiency has been studied in many cohorts ranging from 49 to 4426 individuals with familial or non-familial intellectual disability. Recently these studies were summarized by <xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2014.715">van de Kamp et al [2014]</xref>:</p>
          <list list-type="bullet">
            <list-item>
              <p>Three studies of X-linked families found CRTR deficiency in eight out of 408 cases, for a prevalence of 2.0% (CI 0.6-3.3);</p>
            </list-item>
            <list-item>
              <p>Six studies of cohorts with intellectual disability found CRTR deficiency in 15 out of 1102 cases, for a prevalence of 1.4% (CI 0.7-2.0).</p>
            </list-item>
          </list>
          <p>These studies together with two miscellaneous cohorts resulted in 28 positive cases out of 7218, for a prevalence of 0.4% (CI 0.2-0.5).</p>
        </sec>
      </sec>
      <sec id="creatine.Genetically_Related_Allelic_Dis">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants in <italic toggle="yes">GAMT</italic>, <italic toggle="yes">GATM,</italic> or <italic toggle="yes">SLC6A8.</italic></p>
      </sec>
      <sec id="creatine.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Secondary (cerebral) creatine deficiencies have been observed in <related-object link-type="booklink" source-id="gene" document-id="args-aciduria" document-type="chapter">argininosuccinate lyase deficiency</related-object> (ASL) and argininosuccinate synthetase deficiency (<related-object link-type="booklink" source-id="gene" document-id="ctlm" document-type="chapter">citrullinemia type 1</related-object>) [<xref ref-type="bibr" rid="creatine.REF.van_spronsen.2006.274">van Spronsen et al 2006</xref>], ornithine aminotransferase deficiency (gyrate atrophy of the choroid and retina) [<xref ref-type="bibr" rid="creatine.REF.n_ntosalonen.1999.303">N&#x000e4;nto-Salonen et al 1999</xref>] and &#x00394;(1)-pyrroline-5-carboxylate synthetase (P5CS) deficiency [<xref ref-type="bibr" rid="creatine.REF.martinelli.2012.761">Martinelli et al 2012</xref>].</p>
        <p><xref ref-type="bibr" rid="creatine.REF.boenzi.2012.647">Boenzi et al [2012]</xref> measured plasma creatine levels in individuals with <related-object link-type="booklink" source-id="gene" document-id="otc-def" document-type="chapter">ornithine transcarbamylase</related-object> (OTC), <related-object link-type="booklink" source-id="gene" document-id="ctlm" document-type="chapter">argininosuccinate synthetase</related-object> (ASS), and <related-object link-type="booklink" source-id="gene" document-id="args-aciduria" document-type="chapter">argininosuccinate lyase</related-object> (ASL) deficiencies; <related-object link-type="booklink" source-id="gene" document-id="hhhs" document-type="chapter">hyperammonemia, hyperornithinemia, homocitrullinuria (HHH) syndrome</related-object>, <related-object link-type="booklink" source-id="gene" document-id="lpi" document-type="chapter">and lysinuric protein intolerance</related-object> (LPI). Individuals with OTC and ASS deficiencies and HHH syndrome showed significant reduction of plasma creatine concentration, whereas individuals with ASL deficiency and LPI had high plasma creatine levels.</p>
        <p>These disorders should be considered in individuals with partial cerebral creatine deficiency in the brain detected by <sup>1</sup>H-MRS, who have normal concentrations of guanidinoacetate (GAA) in the urine, plasma, and CSF and a normal creatine-to-creatinine ratio in urine.</p>
      </sec>
      <sec id="creatine.Management">
        <title>Management</title>
        <sec id="creatine.Evaluations_Following_Initial_D">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To assess the extent of disease and needs of an individual diagnosed with CCDS the following investigations should be performed:</p>
          <list list-type="bullet">
            <list-item>
              <p>Detailed neurologic clinical evaluation for the degree of global developmental delay or intellectual disability, epilepsy, movement disorder, and behavior problems</p>
            </list-item>
            <list-item>
              <p>Neuropsychological assessment of cognition and speech</p>
            </list-item>
            <list-item>
              <p>Video documentation of movement disorder</p>
            </list-item>
            <list-item>
              <p>EEG, if any clinical seizures</p>
            </list-item>
            <list-item>
              <p>Prior to initiation of creatine monohydrate supplementation, glomerular filtration rate (GFR) for baseline assessment of kidney function</p>
            </list-item>
            <list-item>
              <p>Baseline determination of cerebral creatine level by brain <sup>1</sup>H-MRS to document creatine deficiency [<xref ref-type="bibr" rid="creatine.REF.st_ckler.1996.914">St&#x000f6;ckler et al 1996</xref>, <xref ref-type="bibr" rid="creatine.REF.schulze.2001.413">Schulze et al 2001</xref>]</p>
            </list-item>
            <list-item>
              <p>ECG and echocardiogram for cardiac involvement</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="creatine.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>The following are appropriate:</p>
          <list list-type="bullet">
            <list-item>
              <p>Occupational therapy, physiotherapy and speech-language therapy for global developmental delay by physiotherapist, occupational therapist, speech-language therapist</p>
            </list-item>
            <list-item>
              <p>Behavior therapy for behavior problems by developmental pediatrician</p>
            </list-item>
            <list-item>
              <p>Seizure management with antiepileptic drugs by epilepsy specialist</p>
            </list-item>
            <list-item>
              <p>Treatment of movement disorder by movement disorder specialist</p>
            </list-item>
          </list>
          <sec id="creatine.GAMT_Deficiency_1">
            <title>GAMT Deficiency</title>
            <p>Treatment of GAMT deficiency aims to replenish cerebral creatine levels by supplementation with creatine monohydrate and to decrease accumulation of neurotoxic GAA in the central nervous system by ornithine supplementation and protein- or arginine-restricted diet [<xref ref-type="bibr" rid="creatine.REF.schulze.2001.413">Schulze et al 2001</xref>, <xref ref-type="bibr" rid="creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</xref>]. Creatine monohydrate and ornithine supplementation decrease GAA accumulation by competitive inhibition of AGAT enzyme activity. A decrease in the level of GAA in cerebrospinal fluid was reported in two individuals with GAMT deficiency treated with creatine monohydrate and ornithine supplementation and with arginine restriction [<xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2012b.155">Mercimek-Mahmutoglu et al 2012b</xref>, <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2014b.133">Mercimek-Mahmutoglu et al 2014b</xref>].</p>
            <p>Treatment is as follows:</p>
            <list list-type="bullet">
              <list-item>
                <p>Creatine monohydrate in oral doses ranging from 400-800 mg/kg BW/day in three to six divided doses [<xref ref-type="bibr" rid="creatine.REF.stockleripsiroglu.2012">Stockler-Ipsiroglu et al 2012</xref>, <xref ref-type="bibr" rid="creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</xref>]</p>
              </list-item>
              <list-item>
                <p>Supplementation of ornithine ranging from 400-800 mg/kg BW/day. Administration of ornithine is divided into three to six daily doses [<xref ref-type="bibr" rid="creatine.REF.schulze.1998.606">Schulze et al 1998</xref>, <xref ref-type="bibr" rid="creatine.REF.schulze.2001.413">Schulze et al 2001</xref>].</p>
              </list-item>
              <list-item>
                <p>Dietary restriction of arginine to 15-25 mg/kg/day that corresponds to 0.4-0.7 g/kg/day protein intake [<xref ref-type="bibr" rid="creatine.REF.schulze.1998.606">Schulze et al 1998</xref>, <xref ref-type="bibr" rid="creatine.REF.schulze.2001.413">Schulze et al 2001</xref>, <xref ref-type="bibr" rid="creatine.REF.schulze.2003.248">Schulze et al 2003</xref>]</p>
                <list list-type="bullet">
                  <list-item>
                    <p>To prevent protein malnutrition, essential amino acid medical formula should be supplemented (0.5-0.8g/kg/day). Available databases (e.g., the US Department of Agriculture National Nutrient Database) can be used to determine exact arginine content of foods to allow precise calculation of daily arginine intake in individuals with GAMT deficiency [<xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2012b.155">Mercimek-Mahmutoglu et al 2012b</xref>].</p>
                  </list-item>
                  <list-item>
                    <p>Because of the challenges involved in understanding arginine restriction, reading dietary labels, and calculating arginine intake (particularly since arginine content is not always indicated), many centers use protein restriction instead [<xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2012b.155">Mercimek-Mahmutoglu et al 2012b</xref>, <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2014b.133">Mercimek-Mahmutoglu et al 2014b</xref>].</p>
                  </list-item>
                </list>
              </list-item>
            </list>
            <p>
              <bold>Treatment outcome of symptomatic individuals with GAMT deficiency</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Global developmental delay and intellectual disability</bold> improved only in 21% of the individuals. None of the individuals achieved normal development or cognitive functions on treatment [<xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</xref>, <xref ref-type="bibr" rid="creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</xref>].</p>
              </list-item>
              <list-item>
                <p><bold>Seizures.</bold> In 18% of individuals seizures were eliminated; in 49% seizure frequency decreased; 33% of individuals had no improvement in seizures [<xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</xref>, <xref ref-type="bibr" rid="creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</xref>].</p>
              </list-item>
              <list-item>
                <p><bold>Movement disorder.</bold> Improvement was seen in 60% of individuals; in 40% of individuals, there was no change in the movement disorder [<xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</xref>, <xref ref-type="bibr" rid="creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</xref>].</p>
              </list-item>
            </list>
            <p>
              <bold>Treatment outcome of asymptomatic individuals with GAMT deficiency</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Normal neurodevelopmental outcome has been reported in three individuals with GAMT deficiency who were diagnosed and treated in the neonatal periodbased on a positive family history of GAMT deficiency in an older sib [<xref ref-type="bibr" rid="creatine.REF.schulze.2006.719">Schulze et al 2006</xref>, <xref ref-type="bibr" rid="creatine.REF.elgharbawy.2013.215">El-Gharbawy et al 2013</xref>, <xref ref-type="bibr" rid="creatine.REF.viau.2013.255">Viau et al 2013</xref>].</p>
              </list-item>
              <list-item>
                <p>Another asymptomatic sib treated from age eight days showed global developmental delay and hypotonia at age 11 months. The authors suggested compliance problems in this family [<xref ref-type="bibr" rid="creatine.REF.dhar.2009.38">Dhar et al 2009</xref>].</p>
              </list-item>
            </list>
          </sec>
          <sec id="creatine.AGAT_Deficiency_1">
            <title>AGAT Deficiency</title>
            <p>Treatment of AGAT deficiency aims to replenish cerebral creatine levels by supplementation with creatine monohydrate in oral doses ranging from 400 to 800 mg/kg BW/day in three to six divided doses.</p>
            <p><bold>Treatment outcome of symptomatic individuals with AGAT deficiency.</bold> Treatment outcome results were reported in 11 individuals with AGAT deficiency [<xref ref-type="bibr" rid="creatine.REF.battini.2002.326">Battini et al 2002</xref>, <xref ref-type="bibr" rid="creatine.REF.edvardson.2010.228">Edvardson et al 2010</xref>, <xref ref-type="bibr" rid="creatine.REF.verma.2010.186">Verma 2010</xref>, <xref ref-type="bibr" rid="creatine.REF.nouioua.2013.670">Nouioua et al 2013</xref>]. If initiation of treatment was after age ten years, no improvement in cognitive function or intellectual disability was seen [<xref ref-type="bibr" rid="creatine.REF.battini.2002.326">Battini et al 2002</xref>, <xref ref-type="bibr" rid="creatine.REF.edvardson.2010.228">Edvardson et al 2010</xref>, <xref ref-type="bibr" rid="creatine.REF.verma.2010.186">Verma 2010</xref>, <xref ref-type="bibr" rid="creatine.REF.nouioua.2013.670">Nouioua et al 2013</xref>]. Normal cognitive function was reported in a female whose treatment was initiated before age two years [<xref ref-type="bibr" rid="creatine.REF.ndika.2012.48">Ndika et al 2012</xref>]. Muscle weakness was improved in all individuals treated with creatine monohydrate [<xref ref-type="bibr" rid="creatine.REF.edvardson.2010.228">Edvardson et al 2010</xref>, <xref ref-type="bibr" rid="creatine.REF.verma.2010.186">Verma 2010</xref>, <xref ref-type="bibr" rid="creatine.REF.nouioua.2013.670">Nouioua et al 2013</xref>].</p>
            <p><bold>Treatment outcome of asymptomatic individuals with AGAT deficiency.</bold> An asymptomatic sib treated from age four months with creatine monohydrate supplementation therapy had normal neurodevelopment at age 18 months; in contrast, his sisters had already shown signs of developmental delay at this age [<xref ref-type="bibr" rid="creatine.REF.battini.2006.828">Battini et al 2006</xref>].</p>
          </sec>
          <sec id="creatine.CRTR_Deficiency_1">
            <title>CRTR Deficiency</title>
            <p>The goal of treatment is to replenish cerebral creatine levels. Treatment of both males and females with CRTR deficiency with creatine-monohydrate was not successful [<xref ref-type="bibr" rid="creatine.REF.stockleripsiroglu.2012">Stockler-Ipsiroglu et al 2012</xref>]. Only one heterozygous female with learning disability and mildly decreased creatine concentration on brain <sup>1</sup>H-MRS showed mild improvement on neuropsychological testing after 18 weeks of treatment with creatine-monohydrate (250-750 mg/kg/day) [<xref ref-type="bibr" rid="creatine.REF.cecil.2001.401">Cecil et al 2001</xref>]. Additionally, combined arginine and glycine supplementation therapy successfully treated intractable epilepsy in a female with CRTR deficiency [<xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2010a.409">Mercimek-Mahmutoglu et al 2010a</xref>].</p>
            <p>Since the enzymes for creatine biosynthesis are present in the brain [<xref ref-type="bibr" rid="creatine.REF.braissant.2008.230">Braissant &#x00026; Henry 2008</xref>], individuals with CRTR deficiency have been treated with L-arginine and L-glycine, precursors in the biosynthesis of creatine.</p>
            <p>Treatment has included:</p>
            <list list-type="bullet">
              <list-item>
                <p>Creatine monohydrate 100-200 mg/kg BW/day in 3 doses</p>
              </list-item>
              <list-item>
                <p>Arginine (hydrochloride or base) 400 mg/kg BW/day in 3 doses</p>
              </list-item>
              <list-item>
                <p>Glycine 150 mg/kg BW/day in 3 doses</p>
              </list-item>
            </list>
            <p>The authors recommend that all three of the supplements listed above be started together in new patients &#x02013; especially in early childhood &#x02013; to slow disease progression. The clinical effectiveness of treatment with three supplements has not been confirmed.</p>
            <p><bold>Treatment outcome of individuals with CRTR deficiency.</bold> To date 22 males and three females with CRTR deficiency have been treated with L-arginine with or without glycine supplementation [<xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2014.715">van de Kamp et al 2014</xref>].</p>
            <list list-type="bullet">
              <list-item>
                <p>In some patients improvements were reported, but in general results appeared to be discouraging and cerebral creatine was not restored [<xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2014.715">van de Kamp et al 2014</xref>].</p>
              </list-item>
              <list-item>
                <p>Four males and two females with CRTR deficiency treated for 42 months with creatine, arginine, and glycine showed increased muscle mass and improved gross motor skills [<xref ref-type="bibr" rid="creatine.REF.valayannopoulos.2012.151">Valayannopoulos et al 2012</xref>].</p>
              </list-item>
              <list-item>
                <p>Nine males with CRTR deficiency showed improvement in locomotor and personal social IQ subscales [<xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2012.141">van de Kamp et al 2012</xref>].</p>
              </list-item>
              <list-item>
                <p>Combined arginine and glycine supplementation therapy successfully treated intractable epilepsy in a female with CRTR deficiency [<xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2010a.409">Mercimek-Mahmutoglu et al 2010a</xref>].</p>
              </list-item>
            </list>
          </sec>
        </sec>
        <sec id="creatine.Prevention_of_Primary_Manifesta">
          <title>Prevention of Primary Manifestations</title>
          <p>See <xref ref-type="sec" rid="creatine.Treatment_of_Manifestations">Treatment of Manifestations</xref>.</p>
        </sec>
        <sec id="creatine.Surveillance">
          <title>Surveillance</title>
          <p>For patients undergoing treatment:</p>
          <list list-type="bullet">
            <list-item>
              <p>Determination of cerebral creatine level by in vivo <sup>1</sup>H-MRS should be performed:</p>
              <list list-type="bullet">
                <list-item>
                  <p>For individuals with GAMT and AGAT deficiency to monitor cerebral creatine levels during creatine supplementation therapy;</p>
                </list-item>
                <list-item>
                  <p>For individuals with CRTR deficiency to monitor cerebral creatine levels for the assessment of treatment outcome [<xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2010b.s101">Mercimek-Mahmutoglu et al 2010b</xref>, <xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2012.141">van de Kamp et al 2012</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>For GAMT deficiency: growth and nutritional status (plasma GAA levels, amino acids, ammonia, protein, albumin, pre-albumin levels) should be monitored every three to six months.</p>
            </list-item>
            <list-item>
              <p>For CRTR deficiency: plasma GAA levels and plasma amino acids should be monitored every three to six months as high-dose arginine and glycine supplementation can result in increased GAA levels.</p>
            </list-item>
            <list-item>
              <p>Repeat GFR annually for assessment of kidney function while on creatine supplementation therapy to detect possible creatine-associated nephropathy [<xref ref-type="bibr" rid="creatine.REF.barisic.2002.157">Barisic et al 2002</xref>].</p>
            </list-item>
            <list-item>
              <p>Perform neuropsychological assessment of cognitive functions and speech.</p>
            </list-item>
          </list>
        </sec>
        <sec id="creatine.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate neonates at-risk for GAMT deficiency or AGAT deficiency to allow for early diagnosis and treatment.</p>
          <p>Evaluations can include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Molecular genetic testing if the pathogenic variants in the family are known;</p>
            </list-item>
            <list-item>
              <p>Biochemical genetic testing if the pathogenic variants in the family are not known.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="creatine.Related_Genetic_Counseling_Issu">Genetic Counseling</xref> for issues related to evaluation of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="creatine.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Transport of dodecyl creatine ester incorporated into lipid nanocapsules (LNCs) was investigated using an in vitro cell-based blood-brain barrier model. It has been shown that these LNCs can cross the blood-brain barrier and enter brain endothelial cells. In human fibroblasts with deficient SLC6A8 protein function, all or part of the dodecyl creatine ester was released from the LNCs and biotransformed to creatine [<xref ref-type="bibr" rid="creatine.REF.trotierfaurion.2015.185">Trotier-Faurion et al 2015</xref>].</p>
          <p>A brain-specific <italic toggle="yes">Slc6a8</italic> knockout mouse was successfully treated with the cyclocreatine, which is a creatine analog. Brain cyclocreatine and cyclocreatine phosphate were detected on cyclocreatine treatment in the brain-specific <italic toggle="yes">Slc6a8</italic> knockout mice at nine weeks of cyclocreatine treatment compared to the creatine and placebo treatment in the same mice. Cyclocreatine-treated brain-specific <italic toggle="yes">Slc6a8</italic> knockout mice showed improvements in cognitive abilities using novel object recognition and spatial learning and memory tests. Thus, cyclocreatine appears promising as a potential therapy for CRTR deficiency. Clinical trials are underway to prove its use in individuals with CRTR deficiency.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ClinicalTrials.gov">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="creatine.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="creatine.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>GAMT deficiency and AGAT deficiency are inherited in an autosomal recessive manner.</p>
          <p>CRTR deficiency is inherited in an X-linked manner.</p>
        </sec>
        <sec id="creatine.Risk_to_Family_Members__Autosom">
          <title>Risk to Family Members &#x02013; Autosomal Recessive Inheritance</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of a child with GAMT or AGAT deficiency are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">GAMT</italic> or <italic toggle="yes">GATM</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an individual with GAMT or AGAT deficiency has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk that s/he is heterozygous for a <italic toggle="yes">GAMT</italic> or <italic toggle="yes">GATM</italic> pathogenic variant is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> To date, individuals with GAMT or AGAT deficiency have not reproduced.</p>
          <p><bold>Other family members of a proband</bold>. Each sib of the proband&#x02019;s parents is at 50% risk of being a carrier of a <italic toggle="yes">GAMT</italic> or <italic toggle="yes">GATM</italic> pathogenic variant.</p>
        </sec>
        <sec id="creatine.Carrier_Detection">
          <title>Carrier Detection</title>
          <p><bold>Molecular genetic testing.</bold> Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">GAMT</italic> or <italic toggle="yes">GATM</italic> pathogenic variants in the family.</p>
        </sec>
        <sec id="creatine.Risk_to_Family_Members__XLinked">
          <title>Risk to Family Members &#x02013; X-Linked Inheritance</title>
          <p>
            <bold>Parents of a Proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The father of a male with CRTR deficiency will not have the disorder nor will he be hemizygous for the <italic toggle="yes">SLC6A8</italic> pathogenic variant; therefore, he does not require further evaluation/testing.</p>
            </list-item>
            <list-item>
              <p>In a family with more than one affected male, the mother of an affected male is an obligate heterozygote (carrier). Note: if a woman has more than one affected child and no other affected relatives and if the <italic toggle="yes">SLC6A8</italic> pathogenic variant cannot be detected in her leukocyte DNA, she has germline mosaicism; 7% of mothers in a retrospective study of 85 families had somatic/germline mosaicism [<xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</xref>].</p>
            </list-item>
            <list-item>
              <p>If a male is the only affected family member (i.e., a simplex case), several possibilities regarding his mother&#x02019;s genetic status need to be considered:</p>
              <list list-type="bullet">
                <list-item>
                  <p>The affected male has a <italic toggle="yes">de novo</italic>
<italic toggle="yes">SLC6A8</italic> pathogenic variant and his mother is not heterozygous for the variant [<xref ref-type="bibr" rid="creatine.REF.salomons.2003.309">Salomons et al 2003</xref>, <xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</xref>, <xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2014.715">van de Kamp et al 2014</xref>]. <italic toggle="yes">SLC6A8</italic> pathogenic variants occurred <italic toggle="yes">de novo</italic> in 30% of the individuals with CRTR deficiency in the <xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013a.463">van de Kamp et al [2013a]</xref> retrospective study.</p>
                </list-item>
                <list-item>
                  <p>His mother has a <italic toggle="yes">de novo</italic>
<italic toggle="yes">SLC6A8</italic> pathogenic variant, either (a) as a "germline pathogenic variant" (i.e., present at the time of her conception and therefore in every cell of her body); or (b) as "germline mosaicism" (i.e., present in some of her germ cells only) [<xref ref-type="bibr" rid="creatine.REF.betsalel.2008.183">Betsalel et al 2008</xref>, <xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</xref>].</p>
                </list-item>
                <list-item>
                  <p>His mother is heterozygous for an <italic toggle="yes">SLC6A8</italic> pathogenic variant.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Heterozygous mothers may have a history of learning disability or mild intellectual disability or seizures [<xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2010a.409">Mercimek-Mahmutoglu et al 2010a</xref>, <xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2011.264">van de Kamp et al 2011</xref>] (see Clinical Description, <xref ref-type="sec" rid="creatine.CRTR_Deficiency">CRTR Deficiency</xref>, <bold>Heterozygous Females</bold>).</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to sibs depends on the genetic status of the mother.</p>
            </list-item>
            <list-item>
              <p>If the mother of the proband has an <italic toggle="yes">SLC6A8</italic> pathogenic variant, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be affected; females who inherit the pathogenic variant will be heterozygous and may develop clinical findings related to the disorder (see Clinical Description, <xref ref-type="sec" rid="creatine.CRTR_Deficiency">CRTR Deficiency</xref>, <bold>Heterozygous Females</bold>).</p>
            </list-item>
            <list-item>
              <p>If the proband represents a simplex case (i.e., a single occurrence in a family) and if the <italic toggle="yes">SLC6A8</italic> pathogenic variant cannot be detected in the leukocyte DNA of the mother, the risk to sibs is low but greater than that of the general population because of the possibility of germline mosaicism [<xref ref-type="bibr" rid="creatine.REF.betsalel.2008.183">Betsalel et al 2008</xref>].</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> No affected male has reproduced.</p>
          <p>
            <bold>Other family members</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The proband&#x02019;s maternal aunts may be at risk of being heterozygotes (carriers) for the <italic toggle="yes">SLC6A8</italic> pathogenic variant and the aunts&#x02019; offspring, depending on their gender, may be at risk of being heterozygous for the pathogenic variant or of being affected.</p>
            </list-item>
            <list-item>
              <p>In one family, a maternal aunt with verbal memory deficit and a mild confrontational naming weakness was described [deGrauw et al 2003].</p>
            </list-item>
          </list>
        </sec>
        <sec id="creatine.Carrier_Detection_1">
          <title>Carrier Detection</title>
          <p>Molecular genetic testing of at-risk female relatives to determine their genetic status is most informative if the pathogenic variant has been identified in the proband.</p>
          <p>Note: (1) Females who are heterozygous for an <italic toggle="yes">SLC6A8</italic> pathogenic variant may develop clinical findings related to the disorder (see Clinical Description, <xref ref-type="sec" rid="creatine.CRTR_Deficiency">CRTR Deficiency</xref>, <bold>Heterozygous Females</bold>). (2) Identification of female carriers requires either (a) prior identification of the <italic toggle="yes">SLC6A8</italic> pathogenic variant in the family or, (b) if an affected male is not available for testing, molecular genetic testing first by sequence analysis, and if no pathogenic variant is identified, by gene-targeted deletion/duplication analysis.</p>
        </sec>
        <sec id="creatine.Related_Genetic_Counseling_Issu">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="creatine.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of genetic status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are heterozygous or are at risk of being heterozygous.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="creatine.Prenatal_Testing_and_Preimplant">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">GAMT, GATM, or SLC6A8</italic> pathogenic variant(s) have been identified in an affected family member, prenatal testing or preimplantation genetic diagnosis for a pregnancy at increased risk may be an option that a couple may wish to consider.</p>
          <p><bold>Biochemical genetic testing.</bold> Prenatal diagnosis for pregnancies at increased risk for GAMT deficiency is possible by analysis of guanidinoacetate and creatine in amniotic fluid. Amniocentesis for prenatal diagnosis was performed at 15 weeks&#x02019; gestation in the mother of a child age ten years with GAMT deficiency. Guanidinoacetate was 11.43 &#x003bc;mol/L (normal range for 15 weeks of amenorrhea was 2.96 &#x000b1; 0.70 &#x003bc;mol/L) [<xref ref-type="bibr" rid="creatine.REF.cheillan.2006.775">Cheillan et al 2006</xref>].</p>
        </sec>
      </sec>
      <sec id="creatine.Resources">
        <title>Resources</title>
      </sec>
      <sec id="creatine.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="creatine.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>Creatine is synthesized by one of two enzymatic reactions:</p>
          <list list-type="bullet">
            <list-item>
              <p>Transfer of the amidino group from arginine to glycine, yielding guanidinoacetic acid and catalyzed by L-arginine:glycine amidinotransferase (also known as glycine amidinotransferase, mitochondrial, AGAT, or GATM)</p>
            </list-item>
            <list-item>
              <p>Methylation of the amidino group in the guanidinoacetic acid molecule by S-adenosyl-L-methionine:N-guanidinoacetate methyltransferase (also known as guanidinoacetate N-methyltransferase or GAMT)</p>
            </list-item>
          </list>
          <p>Creatine is synthesized primarily in the kidney and pancreas which have high AGAT activity and in liver which has high GAMT activity. Both genes and enzymes have been detected in brain as well [<xref ref-type="bibr" rid="creatine.REF.braissant.2008.230">Braissant &#x00026; Henry 2008</xref>].</p>
          <p>Synthesized creatine is transported via the bloodstream to the organs of utilization (mainly muscle and brain), where it is taken up via sodium- and chloride-dependent creatine transporter 1 (SLC6A8 protein) (<xref ref-type="fig" rid="creatine.F2">Figure 2</xref>) [<xref ref-type="bibr" rid="creatine.REF.wyss.2000.1107">Wyss &#x00026; Kaddurah-Daouk 2000</xref>]. This protein is predominantly expressed in skeletal muscle and kidney, but also found in brain, heart, colon, testis, and prostate. The creatine-phosphocreatine shuttle has a key function in the maintenance of the energy supply to skeletal and cardiac muscle. Muscle cells do not synthesize creatine, but take it up via a special sodium-dependent transporter, the creatine transporter.</p>
          <p>If molecular genetic test results are inconclusive (i.e., if sequence variants of unknown significance are identified), GAMT enzyme activity (in cultured fibroblast or lymphoblasts), AGAT enzyme activity (in lymphoblasts), or creatine uptake in cultured fibroblasts can be assessed [<xref ref-type="bibr" rid="creatine.REF.item.2001.1127">Item et al 2001</xref>, <xref ref-type="bibr" rid="creatine.REF.verhoeven.2003.803">Verhoeven et al 2003</xref>, <xref ref-type="bibr" rid="creatine.REF.verhoeven.2004.441">Verhoeven et al 2004</xref>]. In addition, functional testing has been performed for many <italic toggle="yes">GAMT</italic> and <italic toggle="yes">SLC6A8</italic> variants [<xref ref-type="bibr" rid="creatine.REF.rosenberg.2007.890">Rosenberg et al 2007</xref>, <xref ref-type="bibr" rid="creatine.REF.betsalel.2012.596">Betsalel et al 2012</xref>, <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2012a.433">Mercimek-Mahmutoglu et al 2012a</xref>, <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</xref>, <xref ref-type="bibr" rid="creatine.REF.desroches.2015.2163">Desroches et al 2015</xref>].</p>
          <sec id="creatine.GAMT">
            <title>
              <italic toggle="yes">GAMT</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">GAMT</italic> comprises six exons spanning about 5 kb, forming an open reading frame of 711 nucleotides. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="creatine" object-id="creatine.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Benign variants.</bold> Five variants predicted to be possibly damaging (using in silico analysis tools including p.Pro8Thr, p.Tyr27His p.Met71Val, p.Val95Ile, and p.Thr146Arg) showed normal GAMT enzyme activity using site-directed mutagenesis, and were thus determined to be non-pathogenic [<xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</xref>, <xref ref-type="bibr" rid="creatine.REF.desroches.2015.2163">Desroches et al 2015</xref>].</p>
            <p><bold>Pathogenic variants.</bold> See <xref ref-type="table" rid="creatine.T.selected_gamt_pathogenic_vari">Table 6</xref>. About 60 different pathogenic variants located in various exons have been found in individuals with GAMT deficiency [<xref ref-type="bibr" rid="creatine.REF.carducci.2000.633">Carducci et al 2000</xref>, <xref ref-type="bibr" rid="creatine.REF.item.2004.524">Item et al 2004</xref>, <xref ref-type="bibr" rid="creatine.REF.cheillan.2006.775">Cheillan et al 2006</xref>, <xref ref-type="bibr" rid="creatine.REF.lionfran_ois.2006.1713">Lion-Fran&#x000e7;ois et al 2006</xref>, <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</xref>, <xref ref-type="bibr" rid="creatine.REF.verbruggen.2007.921">Verbruggen et al 2007</xref>, <xref ref-type="bibr" rid="creatine.REF.vodopiutz.2007.773">Vodopiutz et al 2007</xref>, <xref ref-type="bibr" rid="creatine.REF.dhar.2009.38">Dhar et al 2009</xref>, <xref ref-type="bibr" rid="creatine.REF.o_rourke.2009.404">O&#x02019;Rourke et al 2009</xref>, <xref ref-type="bibr" rid="creatine.REF.sempere.2009a.745">Sempere et al 2009a</xref>, <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</xref>, <xref ref-type="bibr" rid="creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</xref>].</p>
            <p><italic toggle="yes">GAMT</italic> pathogenic variants comprise nonsense and missense variants, splice errors, insertions, deletions, and frameshifts. The majority of pathogenic variants (&#x0003e;60%) are missense [<xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2014a.462">Mercimek-Mahmutoglu et al 2014a</xref>, <xref ref-type="bibr" rid="creatine.REF.stockleripsiroglu.2014.16">Stockler-Ipsiroglu et al 2014</xref>].</p>
            <p>The most frequent pathogenic variants were c.327G&#x0003e;A (24%; 23/94 alleles) and c.59G&#x0003e;C (21%; 20/94 alleles), detected in 47 affected individuals; 27 of the 47 affected individuals were homozygous [<xref ref-type="bibr" rid="creatine.REF.carducci.2000.633">Carducci et al 2000</xref>, <xref ref-type="bibr" rid="creatine.REF.item.2004.524">Item et al 2004</xref>, <xref ref-type="bibr" rid="creatine.REF.cheillan.2006.775">Cheillan et al 2006</xref>, <xref ref-type="bibr" rid="creatine.REF.lionfran_ois.2006.1713">Lion-Fran&#x000e7;ois et al 2006</xref>, <xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</xref>, <xref ref-type="bibr" rid="creatine.REF.verbruggen.2007.921">Verbruggen et al 2007</xref>, <xref ref-type="bibr" rid="creatine.REF.vodopiutz.2007.773">Vodopiutz et al 2007</xref>, <xref ref-type="bibr" rid="creatine.REF.dhar.2009.38">Dhar et al 2009</xref>, <xref ref-type="bibr" rid="creatine.REF.o_rourke.2009.404">O&#x02019;Rourke et al 2009</xref>, <xref ref-type="bibr" rid="creatine.REF.sempere.2009a.745">Sempere et al 2009a</xref>].</p>
            <table-wrap id="creatine.T.selected_gamt_pathogenic_vari" orientation="portrait" position="anchor">
              <label>Table 6. </label>
              <caption>
                <p>Selected <italic toggle="yes">GAMT</italic> Pathogenic Variants</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_creatine.T.selected_gamt_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                    <th id="hd_h_creatine.T.selected_gamt_pathogenic_vari_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                    <th id="hd_h_creatine.T.selected_gamt_pathogenic_vari_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_creatine.T.selected_gamt_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.59G&#x0003e;C</td>
                    <td headers="hd_h_creatine.T.selected_gamt_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Trp20Ser</td>
                    <td headers="hd_h_creatine.T.selected_gamt_pathogenic_vari_1_1_1_3" rowspan="3" valign="middle" align="left" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000156.4">NM_000156.4</ext-link>
<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000147.1">NP_000147.1</ext-link></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_creatine.T.selected_gamt_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.327G&#x0003e;A&#x000a0;<sup>1</sup></td>
                    <td headers="hd_h_creatine.T.selected_gamt_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">See footnote 1</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_creatine.T.selected_gamt_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.299_311dup13</td>
                    <td headers="hd_h_creatine.T.selected_gamt_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg105GlyfsTer26</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
                <fn id="creatine.TF.6.1">
                  <label>1. </label>
                  <p>The pathogenic variant c.327G&#x0003e;A changes the last nucleotide of the splice donor site of exon 2. Although no amino acid change is predicted, experimental analysis demonstrated that this one base substitution affects RNA-processing and yields two abnormal transcripts, one from skipping of exon 2 and the other from use of a cryptic splice site in intron 2 [<xref ref-type="bibr" rid="creatine.REF.st_ckler.1996.914">St&#x000f6;ckler et al 1996</xref>].</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Normal gene product.</bold> GAMT, a cytosolic protein, catalyzes the second step of creatine biosynthesis. This enzyme converts guanidinoacetate and S-adenosylmethionine to creatine and S-adenosylhomocysteine. In humans, GAMT is expressed with highest activity in the liver and the pancreas and with lower activity in kidney. It is a monomeric protein of 236 amino acids with a relative molecular mass of 26,000-31,000 [<xref ref-type="bibr" rid="creatine.REF.velichkova.2006.16">Velichkova &#x00026; Himo 2006</xref>].</p>
            <p><bold>Abnormal gene product.</bold> The first affected individual described had severe deficiency of GAMT enzyme activity in the liver [<xref ref-type="bibr" rid="creatine.REF.st_ckler.1996.914">St&#x000f6;ckler et al 1996</xref>]. Following development of an assay for GAMT enzyme activity in skin fibroblasts or Epstein-Barr virus transformed lymphoblasts [<xref ref-type="bibr" rid="creatine.REF.ilas.2000.179">Ilas et al 2000</xref>], undetectable GAMT enzyme activity was identified in 20 individuals with GAMT deficiency [<xref ref-type="bibr" rid="creatine.REF.mercimekmahmutoglu.2006.480">Mercimek-Mahmutoglu et al 2006</xref>].</p>
          </sec>
          <sec id="creatine.GATM">
            <title>
              <italic toggle="yes">GATM</italic>
            </title>
            <p><bold>Gene structure.</bold> The normal <italic toggle="yes">GATM</italic> genomic DNA is 16,858 bp in length and comprises nine exons [<xref ref-type="bibr" rid="creatine.REF.battini.2002.326">Battini et al 2002</xref>]. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="creatine" object-id="creatine.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic variants.</bold> Only seven <italic toggle="yes">GATM</italic> pathogenic variants causing AGAT deficiency have been reported (see <xref ref-type="table" rid="creatine.T.selected_gatm_pathogenic_vari">Table 7</xref>). Five pathogenic variants occurred in the homozygous state.</p>
            <table-wrap id="creatine.T.selected_gatm_pathogenic_vari" orientation="portrait" position="anchor">
              <label>Table 7. </label>
              <caption>
                <p>Selected <italic toggle="yes">GATM</italic> Pathogenic Variants</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_creatine.T.selected_gatm_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                    <th id="hd_h_creatine.T.selected_gatm_pathogenic_vari_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                    <th id="hd_h_creatine.T.selected_gatm_pathogenic_vari_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_creatine.T.selected_gatm_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.446G&#x0003e;A&#x000a0;<sup>2</sup><break/>(9297G&#x0003e;A)</td>
                    <td headers="hd_h_creatine.T.selected_gatm_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Trp149Ter</td>
                    <td headers="hd_h_creatine.T.selected_gatm_pathogenic_vari_1_1_1_3" rowspan="3" valign="middle" align="left" colspan="1">
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_001482.2">NM_001482.2</ext-link>
                      <break/>
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_001473.1">NP_001473.1</ext-link>
                    </td>
                  </tr>
                  <tr>
                    <td headers="hd_h_creatine.T.selected_gatm_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.484+1G&#x0003e;T<break/>(IVS3+1G&#x0003e;T)&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_creatine.T.selected_gatm_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_creatine.T.selected_gatm_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1111dupA&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_creatine.T.selected_gatm_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Met371AsnfsTer6</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
                <fn id="creatine.TF.7.1">
                  <label>1. </label>
                  <p>Variant designation that does not conform to current naming conventions</p>
                </fn>
                <fn id="creatine.TF.7.2">
                  <label>2. </label>
                  <p>The c.446G&#x0003e;A pathogenic nonsense variant predicts a severely truncated protein lacking the active-site cysteine residue 407 [<xref ref-type="bibr" rid="creatine.REF.item.2001.1127">Item et al 2001</xref>].</p>
                </fn>
                <fn id="creatine.TF.7.3">
                  <label>3. </label>
                  <p>Nucleotide change results in skipping of exon 3 at the RNA level (r.289_484del196) [<xref ref-type="bibr" rid="creatine.REF.johnston.2005">Johnston et al 2005</xref>].</p>
                </fn>
                <fn id="creatine.TF.7.4">
                  <label>4. </label>
                  <p>
                    <xref ref-type="bibr" rid="creatine.REF.edvardson.2010.228">Edvardson et al [2010]</xref>
                  </p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Normal gene product.</bold> AGAT catalyzes the first reaction in creatine biosynthesis and transfers amidino group from arginine to glycine to form ornithine and guanidinoacetate. Guanidinocetate is the precursor of creatine. Mainly found in kidney, AGAT is located in the cytosol and in the intermembrane space of mitochondria. AGAT is the rate-limiting enzyme of creatine biosynthesis. AGAT enzyme activity is inhibited by creatine via expression of the protein in mRNA level. AGAT enzyme activity is inhibited by ornithine allosterically.</p>
            <p>Human mitochondrial AGAT is synthesized as a precursor of 423 amino acids from which the N-terminal 37 residues are cleaved off when the protein is transported to the mitochondrial intermembrane space, yielding a mature protein of 386 amino acid residues. The cytosolic form of AGAT consists of 391 amino acids [<xref ref-type="bibr" rid="creatine.REF.humm.1997.3373">Humm et al 1997</xref>].</p>
            <p><bold>Abnormal gene product.</bold> The effect of two reported pathogenic alleles (p.Trp149Ter and p.Ala97ValfsTer11) showed no detectable enzyme activity in the cultivated lymphoblasts [<xref ref-type="bibr" rid="creatine.REF.item.2001.1127">Item et al 2001</xref>, <xref ref-type="bibr" rid="creatine.REF.battini.2002.326">Battini et al 2002</xref>, <xref ref-type="bibr" rid="creatine.REF.ndika.2012.48">Ndika et al 2012</xref>]. Cell extracts from the obligate carrier parents of the first described Italian family showed intermediate residual enzyme activity, as would be expected for the heterozygous state [<xref ref-type="bibr" rid="creatine.REF.item.2001.1127">Item et al 2001</xref>, <xref ref-type="bibr" rid="creatine.REF.battini.2002.326">Battini et al 2002</xref>].</p>
          </sec>
          <sec id="creatine.SLC6A8">
            <title>
              <italic toggle="yes">SLC6A8</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">SLC6A8</italic> comprises 13 exons and spans 8.4 kb. The SLC6A8 mRNA is 3580 bp (reference sequence <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_005629.3">NM_005629.3</ext-link>) [<xref ref-type="bibr" rid="creatine.REF.salomons.2001.1497">Salomons et al 2001</xref>]. <italic toggle="yes">SLC6A8,</italic> on chromosome Xq28, has a pseudogene <italic toggle="yes">SLC6A10</italic> (on chromosome 16p11.2) which has a premature stop codon in exon 4 [<xref ref-type="bibr" rid="creatine.REF.clark.2006.604">Clark et al 2006</xref>]. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="creatine" object-id="creatine.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic variants.</bold> The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.lovd.nl/SLC6A8">LOVD Database</ext-link> lists 65 reported pathogenic variants from 85 families with SLC6A8 deficiency [<xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013b.155">van de Kamp et al 2013b</xref>]. The most common pathogenic variants were missense (31%) and three-base pair (in-frame) deletions (24%) [<xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</xref>]. Certain pathogenic variants have been detected in several unrelated families. For example, c.1006_1008delAAC (in 5 families) and c.1222_1224delTTC (in 7 families) both result in the deletion of a three-nucleotide duplication [<xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013b.155">van de Kamp et al 2013b</xref>]. The pathogenic nature of many missense variants has been established by overexpression in primary SLC6A8-deficient cells for 20 missense variants [<xref ref-type="bibr" rid="creatine.REF.rosenberg.2007.890">Rosenberg et al 2007</xref>, <xref ref-type="bibr" rid="creatine.REF.betsalel.2011.56">Betsalel et al 2011</xref>, <xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</xref>].</p>
            <p>Single-exon deletions up to whole-gene deletions and even contiguous gene deletion have been reported [<xref ref-type="bibr" rid="creatine.REF.anselm.2006.214">Anselm et al 2006</xref>, <xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2015.141">van de Kamp et al 2015</xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.lovd.nl/SLC6A8">LOVD Database</ext-link>].</p>
            <table-wrap id="creatine.T.selected_slc6a8_pathogenic_va" orientation="portrait" position="anchor">
              <label>Table 8. </label>
              <caption>
                <p>Selected <italic toggle="yes">SLC6A8</italic> Pathogenic Variants</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                    <th id="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                    <th id="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.321_323delCTT<break/>(319_321delCTT)</td>
                    <td headers="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Phe107del</td>
                    <td headers="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_3" rowspan="4" valign="middle" align="left" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_005629.3">NM_005629.3</ext-link>
<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_005620.1">NP_005620.1</ext-link></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1222_1224delTTC<break/>(1221_1223delTTC)</td>
                    <td headers="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Phe408del</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1631C&#x0003e;T</td>
                    <td headers="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Pro544Leu</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1661C&#x0003e;T</td>
                    <td headers="hd_h_creatine.T.selected_slc6a8_pathogenic_va_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Pro554Leu</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
                <fn id="creatine.TF.8.1">
                  <label>1. </label>
                  <p>Variant designation that does not conform to current naming conventions</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Normal gene product.</bold> The SLC6A8 protein is a member of a solute carrier family of Na+ and Cl- dependent transporters responsible for the uptake of certain neurotransmitters (noradrenalin, serotonin, GABA, dopamine) and amino acids (glycine, proline, taurine) [<xref ref-type="bibr" rid="creatine.REF.nash.1994.165">Nash et al 1994</xref>]. The SLC6A8 protein comprises 635 amino acids with a molecular weight of 70 kd.</p>
            <p><bold>Abnormal gene product.</bold> All pathogenic variants resulted in impaired creatine uptake in fibroblasts when cultured at physiologic levels of creatine [<xref ref-type="bibr" rid="creatine.REF.salomons.2003.309">Salomons et al 2003</xref>, <xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2013a.463">van de Kamp et al 2013a</xref>]. In the presence of a strong suspicion of CRTR deficiency in a male (e.g., elevated urine creatine-to-creatinine ratio or creatine deficiency in the brain <sup>1</sup>H-MRS) with no detected pathogenic variant or with a novel variant of uncertain pathogenicity, creatine uptake studies in cultured fibroblasts are important in the assessment of CRTR deficiency. In males the creatine uptake is less than 10% of normal control fibroblasts (incubated with 25 &#x000b5;mol creatine) [<xref ref-type="bibr" rid="creatine.REF.salomons.2001.1497">Salomons et al 2001</xref>, <xref ref-type="bibr" rid="creatine.REF.rosenberg.2007.890">Rosenberg et al 2007</xref>]. This testing may also be valuable in a symptomatic heterozygous female with a novel variant of uncertain pathogenicity, but due to skewed X-inactivation a normal creatine uptake does not rule out CRTR deficiency.</p>
          </sec>
        </sec>
      </sec>
      <sec id="creatine.References">
        <title>References</title>
        <sec id="creatine.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="creatine.Literature_Cited.reflist0">
            <ref id="creatine.REF.akiyama.2014.65">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Akiyama</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osaka</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimbo</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakajiri</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kobayashi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oka</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Endoh</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshinaga</surname>
                    <given-names>H.</given-names>
                  </name>
                </person-group>
                <article-title>A Japanese adult case of guanidinoacetate methyltransferase deficiency.</article-title>
                <source>JIMD Rep.</source>
                <year>2014</year>
                <volume>12</volume>
                <fpage>65</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">23846910</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.almeida.2004.214">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Almeida</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verhoeven</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roos</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valongo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cardoso</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vilarinho</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Creatine and guanidinoacetate: diagnostic markers for inborn errors in creatine biosynthesis and transport.</article-title>
                <source>Mol Genet Metab</source>
                <volume>82</volume>
                <fpage>214</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15234334</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.anselm.2006.214">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Anselm</surname>
                    <given-names>IA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alkuraya</surname>
                    <given-names>FS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fulton</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazumdar</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivkin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frye</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poussaint</surname>
                    <given-names>TY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsden</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>X-linked creatine transporter defect: a report on two unrelated boys with a severe clinical phenotype.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2006</year>
                <volume>29</volume>
                <fpage>214</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16601897</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.anselm.2008.1642">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Anselm</surname>
                    <given-names>IA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coulter</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Darras</surname>
                    <given-names>BT</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Cardiac manifestations in a child with a novel mutation in creatine transporter gene SLC6A8.</article-title>
                <source>Neurology.</source>
                <volume>70</volume>
                <fpage>1642</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">18443316</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.barisic.2002.157">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Barisic</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernert</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ipsiroglu</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stromberger</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gruber</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prayer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bittner</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stockler-Ipsiroglu</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Effects of oral creatine supplementation in a patient with MELAS phenotype and associated nephropathy.</article-title>
                <source>Neuropediatrics</source>
                <volume>33</volume>
                <fpage>157</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">12200746</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.battini.2006.828">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Battini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alessandr&#x000ec;</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leuzzi</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moro</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tosetti</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bianchi</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cioni</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Arginine:glycine amidinotransferase (AGAT) deficiency in a newborn: early treatment can prevent phenotypic expression of the disease.</article-title>
                <source>J Pediatr.</source>
                <year>2006</year>
                <volume>148</volume>
                <fpage>828</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">16769397</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.battini.2002.326">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Battini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leuzzi</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carducci</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tosetti</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bianchi</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Item</surname>
                    <given-names>CB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stockler-Ipsiroglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cioni</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Creatine depletion in a new case with AGAT deficiency: clinical and genetic study in a large pedigree.</article-title>
                <source>Mol Genet Metab</source>
                <volume>77</volume>
                <fpage>326</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">12468279</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.betsalel.2011.56">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Betsalel</surname>
                    <given-names>OT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenberg</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Almeida</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleefstra</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valayannopoulos</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdul-Rahman</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poplawski</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vilarinho</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolf</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>den Dunnen</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Characterization of novel SLC6A8 variants with the use of splice-site analysis tools and implementation of a newly developed LOVD database.</article-title>
                <source>Eur J Hum Genet.</source>
                <volume>19</volume>
                <fpage>56</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">20717164</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.betsalel.2012.596">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Betsalel</surname>
                    <given-names>OT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pop</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenberg</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fernandez-Ojeda</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Creatine Transporter Research, Group, Jakobs C, Salomons GS. Detection of variants in SLC6A8 and functional analysis of unclassified missense variants.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2012</year>
                <volume>105</volume>
                <fpage>596</fpage>
                <lpage>601</lpage>
                <pub-id pub-id-type="pmid">22281021</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.betsalel.2008.183">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Betsalel</surname>
                    <given-names>OT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van de Kamp</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mart&#x000ed;nez-Mu&#x000f1;oz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenberg</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Brouwer</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pouwels</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Knaap</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancini</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamel</surname>
                    <given-names>BC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Detection of low-level somatic and germline mosaicism by denaturing high-performance liquid chromatography in a EURO-MRX family with SLC6A8 deficiency.</article-title>
                <source>Neurogenetics.</source>
                <volume>9</volume>
                <fpage>183</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">18350323</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.boenzi.2012.647">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boenzi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastore</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinelli</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goffredo</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boiani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rizzo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dionisi-Vici</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Creatine metabolism in urea cycle defects.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>35</volume>
                <fpage>647</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">22644604</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.braissant.2008.230">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Braissant</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henry</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>AGAT, GAMT and SLC6A8 distribution in the central nervous system, in relation to creatine deficiency syndromes: a review.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>31</volume>
                <fpage>230</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18392746</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.caldeira_ara_jo.2005.122">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Caldeira Ara&#x000fa;jo</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smit</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verhoeven</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silva</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vasconcelos</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tom&#x000e1;s</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tavares de Almeida</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Guanidinoacetate methyltransferase deficiency identified in adults and a child with mental retardation.</article-title>
                <source>Am J Med Genet A.</source>
                <volume>133A</volume>
                <fpage>122</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15651030</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.carducci.2000.633">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carducci</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leuzzi</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carducci</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prudente</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mercuri</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antonozzi</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Two new severe mutations causing guanidinoacetate methyltransferase deficiency.</article-title>
                <source>Mol Genet Metab</source>
                <volume>71</volume>
                <fpage>633</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11136556</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.cecil.2001.401">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cecil</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ball</surname>
                    <given-names>WS</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chuck</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verhoeven</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DeGrauw</surname>
                    <given-names>TJ</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Irreversible brain creatine deficiency with elevated serum and urine creatine: a creatine transporter defect?</article-title>
                <source>Ann Neurol</source>
                <volume>49</volume>
                <fpage>401</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">11261517</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.cheillan.2006.775">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cheillan</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Acquaviva</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boisson</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roth</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cordier</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Francois</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vianey-Saban</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Prenatal diagnosis of guanidinoacetate methyltransferase deficiency: increased guanidinoacetate concentrations in amniotic fluid.</article-title>
                <source>Clin Chem</source>
                <volume>52</volume>
                <fpage>775</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16595836</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.cheillan.2012.96">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cheillan</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joncquel-Chevalier Curt</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Briand</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mention-Mulliez</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dobbelaere</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cuisset</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lion-Fran&#x000e7;ois</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Portes</surname>
                    <given-names>VD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chabli</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valayannopoulos</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benoist</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pinard</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simard</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Douay</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deiva</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Afenjar</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>H&#x000e9;ron</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivier</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chabrol</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prieur</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cartault</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pitelet</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldenberg</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bekri</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerard</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delorme</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tardieu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porchet</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vianey-Saban</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vamecq</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Screening for primary creatine deficiencies in French patients with unexplained neurological symptoms.</article-title>
                <source>Orphanet J Rare Dis.</source>
                <year>2012</year>
                <volume>7</volume>
                <fpage>96</fpage>
                <pub-id pub-id-type="pmid">23234264</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.clark.2006.604">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Clark</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenberg</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Almeida</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>TC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stevenson</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>X-linked creatine transporter (SLC6A8) mutations in about 1% of males with mental retardation of unknown etiology.</article-title>
                <source>Hum Genet</source>
                <volume>119</volume>
                <fpage>604</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">16738945</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.cognat.2004.1459">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cognat</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheillan</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piraud</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roos</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vianey-Saban</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Determination of guanidinoacetate and creatine in urine and plasma by liquid chromatography-tandem mass spectrometry.</article-title>
                <source>Clin Chem</source>
                <volume>50</volume>
                <fpage>1459</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">15277360</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.comeaux.2013.260">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Comeaux</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleppe</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>VW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmitt</surname>
                    <given-names>ES</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Craigen</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renaud</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sun</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Biochemical, molecular, and clinical diagnoses of patients with cerebral creatine deficiency syndromes.</article-title>
                <source>Mol Genet Metab</source>
                <volume>109</volume>
                <fpage>260</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">23660394</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.degrauw.2003.45">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>deGrauw</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cecil</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byars</surname>
                    <given-names>AW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ball</surname>
                    <given-names>WS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>The clinical syndrome of creatine transporter deficiency.</article-title>
                <source>Mol Cell Biochem</source>
                <volume>244</volume>
                <fpage>45</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">12701808</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.desroches.2015.2163">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Desroches</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patel</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marshall</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mercimek-Mahmutoglu</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Carrier frequency of guanidinoacetate methyltransferase deficiency in the general population by functional characterization of missense variants in the GAMT gene.</article-title>
                <source>Mol Genet Genomics.</source>
                <year>2015</year>
                <volume>290</volume>
                <fpage>2163</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">26003046</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.dhar.2009.38">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dhar</surname>
                    <given-names>SU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scaglia</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>FY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barshop</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haas</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hunter</surname>
                    <given-names>JV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lotze</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maranda</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willis</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdenur</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O&#x02019;Brien</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Expanded clinical and molecular spectrum of guanidinoacetate methyltransferase (GAMT) deficiency.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>96</volume>
                <fpage>38</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">19027335</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.edvardson.2010.228">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Edvardson</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korman</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Livne</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shaag</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saada</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nalbandian</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allouche-Arnon</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gomori</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katz-Brull</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>L-arginine:glycine amidinotransferase (AGAT) deficiency: clinical presentation and response to treatment in two patients with a novel mutation.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2010</year>
                <volume>101</volume>
                <fpage>228</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">20682460</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.elgharbawy.2013.215">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>El-Gharbawy</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldstein</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Millington</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaisnins</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlune</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barshop</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schulze</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koeberl</surname>
                    <given-names>DD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>SP</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Elevation of guanidinoacetate in newborn dried blood spots and impact of early treatment in GAMT deficiency.</article-title>
                <source>Mol Genet Metab</source>
                <volume>109</volume>
                <fpage>215</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">23583224</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.engelke.2009.538">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Engelke</surname>
                    <given-names>UF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tassini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayek</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Vries</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bilos</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vivi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valensin</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buoni</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zannolli</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brussel</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kremer</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Veendrick-Meekes</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kluijtmans</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morava</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wevers</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Guanidinoacetate methyltransferase (GAMT) deficiency diagnosed by proton NMR spectroscopy of body fluids.</article-title>
                <source>NMR Biomed.</source>
                <volume>22</volume>
                <fpage>538</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">19288536</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.fons.2009.2168">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fons</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sempere</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanmart&#x000ed;</surname>
                    <given-names>FX</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arias</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>P&#x000f3;o</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pineda</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribes</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merinero</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vilaseca</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Artuch</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campistol</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Epilepsy spectrum in cerebral creatine transporter deficiency.</article-title>
                <source>Epilepsia.</source>
                <volume>50</volume>
                <fpage>2168</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">19706062</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.hahn.2002.1349">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hahn</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tackels-Horne</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>TC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>HA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schroer</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lubs</surname>
                    <given-names>HA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olson</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holden</surname>
                    <given-names>KR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stevenson</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>CE</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>X-linked mental retardation with seizures and carrier manifestations is caused by a mutation in the creatine-transporter gene (SLC6A8) located in Xq28.</article-title>
                <source>Am J Hum Genet.</source>
                <volume>70</volume>
                <fpage>1349</fpage>
                <lpage>56</lpage>
                <pub-id pub-id-type="pmid">11898126</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.humm.1997.3373">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Humm</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fritsche</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinbacher</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huber</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Crystal structure and mechanism of human L-arginine:glycine amidinotransferase: a mitochondrial enzyme involved in creatine biosynthesis.</article-title>
                <source>EMBO J.</source>
                <volume>16</volume>
                <fpage>3373</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">9218780</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.ilas.2000.179">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ilas</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;hl</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>St&#x000f6;ckler-Ipsiroglu</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Guanidinoacetate methyltransferase (GAMT) deficiency: non-invasive enzymatic diagnosis of a newly recognized inborn error of metabolism.</article-title>
                <source>Clin Chim Acta.</source>
                <volume>290</volume>
                <fpage>179</fpage>
                <lpage>88</lpage>
                <pub-id pub-id-type="pmid">10660808</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.item.2004.524">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Item</surname>
                    <given-names>CB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mercimek-Mahmutoglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Battini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edlinger-Horvat</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stromberger</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bodamer</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;hl</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vilaseca</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korall</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>St&#x000f6;ckler-Ipsiroglu</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Characterization of seven novel mutations in seven patients with GAMT deficiency.</article-title>
                <source>Hum Mutat.</source>
                <volume>23</volume>
                <fpage>524</fpage>
                <pub-id pub-id-type="pmid">15108290</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.item.2001.1127">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Item</surname>
                    <given-names>CB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>St&#x000f6;ckler-Ipsiroglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stromberger</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muhl</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alessandri</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bianchi</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tosetti</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fornai</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cioni</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Arginine:Glycine amindinotransferase (AGAT) deficiency: The third inborn error of creatine metabolism in humans.</article-title>
                <source>Am J Hum Genet</source>
                <volume>69</volume>
                <fpage>1127</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">11555793</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.johnston.2005">
              <mixed-citation publication-type="confproc">Johnston K, Plawner L, Cooper L, Salomons GS, Verhoeven NM, Jakobs C, Barkovich AJ. The second family with AGAT deficiency (creatine biosynthesis defect): diagnosis, treatment and the first prenatal diagnosis. Abstract 205. Salt Lake City, UT: American Society of Human Genetics 55th Annual Meeting; 2005.</mixed-citation>
            </ref>
            <ref id="creatine.REF.kleefstra.2005.379">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kleefstra</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenberg</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stroink</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Bokhoven</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamel</surname>
                    <given-names>BC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Vries</surname>
                    <given-names>BB</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Progressive intestinal, neurological and psychiatric problems in two adult males with cerebral creatine deficiency caused by an SLC6A8 mutation.</article-title>
                <source>Clin Genet</source>
                <volume>68</volume>
                <fpage>379</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">16143026</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.lionfran_ois.2006.1713">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lion-Fran&#x000e7;ois</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheillan</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pitelet</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Acquaviva-Bourdain</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bussy</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cotton</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guibaud</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000e9;rard</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivier</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vianey-Saban</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>des Portes</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>High frequency of creatine deficiency syndromes in patients with unexplained mental retardation.</article-title>
                <source>Neurology.</source>
                <volume>67</volume>
                <fpage>1713</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">17101918</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.mancardi.2007.1211">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mancardi</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caruso</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schiaffino</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baglietto</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Battaglia</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zara</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Veneselli</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaggero</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Severe epilepsy in X-linked creatine transporter defect (CRTR-D).</article-title>
                <source>Epilepsia</source>
                <volume>48</volume>
                <fpage>1211</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">17553121</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.mancini.2005.288">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mancini</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Catsman-Berrevoets</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Coo</surname>
                    <given-names>IF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aarsen</surname>
                    <given-names>FK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamphoven</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huijmans</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Knaap</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Two novel mutations in SLC6A8 cause creatine transporter defect and distinctive X-linked mental retardation in two unrelated Dutch families.</article-title>
                <source>Am J Med Genet A.</source>
                <volume>132A</volume>
                <fpage>288</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">15690373</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.martinelli.2012.761">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Martinelli</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>H&#x000e4;berle</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubio</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giunta</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hausser</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carrozzo</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gougeard</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marco-Mar&#x000ed;n</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goffredo</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meschini</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bevivino</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boenzi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colafati</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brancati</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baumgartner</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dionisi-Vici</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Understanding pyrroline-5-carboxylate synthetase deficiency: clinical, molecular, functional, and expression studies, structure-based analysis, and novel therapy with arginine.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>35</volume>
                <fpage>761</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">22170564</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.mercimekmahmutoglu.2010a.409">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mercimek-Mahmutoglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Connolly</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poskitt</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horvath</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lowry</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casey</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sinclair</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davis</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stockler-Ipsiroglu</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2010a</year>
                <article-title>Treatment of intractable epilepsy in a female with SLC6A8 deficiency.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>101</volume>
                <fpage>409</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">20846889</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.mercimekmahmutoglu.2006.480">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mercimek-Mahmutoglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stoeckler-Ipsiroglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adami</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Appleton</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Araujo</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ensenauer</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fernandez-Alvarez</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grolik</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Item</surname>
                    <given-names>CB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leuzzi</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marquardt</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muhl</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saelke-Kellermann</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schulze</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Surtees</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Knaap</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vasconcelos</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verhoeven</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vilarinho</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilichowski</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>GAMT deficiency: features, treatment, and outcome in an inborn error of creatine synthesis.</article-title>
                <source>Neurology</source>
                <volume>67</volume>
                <fpage>480</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">16855203</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.mercimekmahmutoglu.2010b.s101">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mercimek-Mahmutoglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roland</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huh</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinraths</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Connolly</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sinclair</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stockler-Ipsiroglu</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2010b</year>
                <article-title>Six new patients with creatine deficiency syndromes identified by selective screening in British Columbia.</article-title>
                <source>J Inh Metab Dis</source>
                <volume>33</volume>
                <fpage>S101</fpage>
              </element-citation>
            </ref>
            <ref id="creatine.REF.mercimekmahmutoglu.2012a.433">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mercimek-Mahmutoglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sinclair</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Dooren</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanhai</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ashcraft</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michel</surname>
                    <given-names>OJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Betsalel</surname>
                    <given-names>OT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sweetman</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                </person-group>
                <year>2012a</year>
                <article-title>Guanidinoacetate methyltransferase deficiency: first steps to newborn screening for a treatable neurometabolic disease.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>107</volume>
                <fpage>433</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">23031365</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.mercimekmahmutoglu.2012b.155">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mercimek-Mahmutoglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dunbar</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friesen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garret</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hartnett</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huh</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sinclair</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stockler</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wellington</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pouwels</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2012b</year>
                <article-title>Evaluation of two year treatment outcome and limited impact of arginine restriction in a patient with GAMT deficiency.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>105</volume>
                <fpage>155</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">22019491</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.mercimekmahmutoglu.2014a.462">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mercimek-Mahmutoglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ndika</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanhai</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Villemeur</surname>
                    <given-names>TB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheillan</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christensen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dorison</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hannig</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hendriks</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hofstede</surname>
                    <given-names>FC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lion-Francois</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lund</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mundy</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pitelet</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raspall-Chaure</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott-Schwoerer</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szakszon</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valayannopoulos</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                </person-group>
                <article-title>Thirteen new patients with guanidinoacetate methyltransferase deficiency and functional characterization of nineteen novel missense variants in the GAMT gene.</article-title>
                <source>Hum Mutat.</source>
                <year>2014a</year>
                <volume>35</volume>
                <fpage>462</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">24415674</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.mercimekmahmutoglu.2014b.133">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mercimek-Mahmutoglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2014b</year>
                <article-title>Case study for the evaluation of current treatment recommendations of guanidinoacetate methyltransferase deficiency: ineffectiveness of sodium benzoate.</article-title>
                <source>Pediatr Neurol</source>
                <volume>51</volume>
                <fpage>133</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">24766785</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.m_rkrid.2015.760">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>M&#x000f8;rkrid</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rowe</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elgstoen</surname>
                    <given-names>KB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olesen</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruijter</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hall</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tortorelli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schulze</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kyriakopoulou</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wamelink</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van de Kamp</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rinaldo</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2015</year>
                <article-title>Continuous age- and sex-adjusted reference intervals of urinary markers for cerebral creatine deficiency syndromes: a novel approach to the definition of reference intervals.</article-title>
                <source>Clin Chem.</source>
                <volume>61</volume>
                <fpage>760</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">25759465</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.n_ntosalonen.1999.303">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>N&#x000e4;nto-Salonen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Komu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lundbom</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hein&#x000e4;nen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alanen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sipil&#x000e4;</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simell</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <article-title>Reduced brain creatine in gyrate atrophy of the choroid and retina with hyperornithinemia.</article-title>
                <source>Neurology.</source>
                <year>1999</year>
                <volume>53</volume>
                <fpage>303</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">10430418</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.nash.1994.165">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nash</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giros</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kingsmore</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rochelle</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suter</surname>
                    <given-names>ST</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregor</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seldin</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caron</surname>
                    <given-names>MG</given-names>
                  </name>
                </person-group>
                <year>1994</year>
                <article-title>Cloning, pharmacological characterization, and genomic localization of the human creatine transporter.</article-title>
                <source>Receptors Channels.</source>
                <volume>2</volume>
                <fpage>165</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">7953292</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.nasrallah.2012.427">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nasrallah</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kraoua</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joncquel-Chevalier Curt</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bout</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taieb</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khouja</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Briand</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaabachi</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Guanidinoacetate methyltransferase (GAMT) deficiency in two Tunisian siblings: clinical and biochemical features.</article-title>
                <source>Clin Lab</source>
                <volume>58</volume>
                <fpage>427</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">22783571</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.ndika.2012.48">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ndika</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnston</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barkovich</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wirt</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O&#x02019;Neill</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Betsalel</surname>
                    <given-names>OT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                </person-group>
                <article-title>Developmental progress and creatine restoration upon long-term creatine supplementation of a patient with arginine:glycine amidinotransferase deficiency.</article-title>
                <source>Mol Genet Metab</source>
                <year>2012</year>
                <volume>106</volume>
                <fpage>48</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">22386973</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.nouioua.2013.670">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nouioua</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheillan</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zaouidi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amedjout</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kessaci</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boulahdour</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamadouche</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tazir</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Creatine deficiency syndrome. A treatable myopathy due to arginine-glycine amidinotransferase (AGAT) deficiency.</article-title>
                <source>Neuromuscul Disord</source>
                <volume>23</volume>
                <fpage>670</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">23770102</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.o_rourke.2009.404">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>O&#x02019;Rourke</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ryan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monavari</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>MD</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Guanidinoacetate methyltransferase (GAMT) deficiency: late onset of movement disorder and preserved expressive language.</article-title>
                <source>Dev Med Child Neurol</source>
                <volume>51</volume>
                <fpage>404</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">19388150</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.pitt.2014.303">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pitt</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tzanakos</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nguyen</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Newborn screening for guanidinoacetate methyl transferase deficiency.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>111</volume>
                <fpage>303</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">24477282</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.puusepp.2010.s5">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Puusepp</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kall</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Talvik</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000e4;nnamaa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rein</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ounap</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>The screening of SLC6A8 deficiency among Estonian families with X-linked mental retardation.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>33</volume>
                <supplement>Suppl 3</supplement>
                <fpage>S5</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">24137762</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.rosenberg.2007.890">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rosenberg</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mart&#x000ed;nez Mu&#x000f1;oz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Betsalel</surname>
                    <given-names>OT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Dooren</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fernandez</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>deGrauw</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleefstra</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Functional characterization of missense variants in the creatine transporter gene (SLC6A8): improved diagnostic application.</article-title>
                <source>Hum Mutat</source>
                <volume>28</volume>
                <fpage>890</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">17465020</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.salomons.2001.1497">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Dooren</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verhoeven</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cecil</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ball</surname>
                    <given-names>WS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Degrauw</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>X-linked creatine-transporter gene (SLC6A8) defect: a new creatine-deficiency syndrome.</article-title>
                <source>Am J Hum Genet</source>
                <volume>68</volume>
                <fpage>1497</fpage>
                <lpage>500</lpage>
                <pub-id pub-id-type="pmid">11326334</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.salomons.2003.309">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Dooren</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verhoeven</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsden</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cecil</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DeGrauw</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>X-linked creatine transporter defect: an overview.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>26</volume>
                <fpage>309</fpage>
                <lpage>18</lpage>
                <pub-id pub-id-type="pmid">12889669</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.schulze.2003.248">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schulze</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bachert</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlemmer</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harting</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Polster</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verhoeven</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fowler</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayatepek</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Lack of creatine in muscle and brain in an adult with GAMT deficiency.</article-title>
                <source>Ann Neurol</source>
                <volume>53</volume>
                <fpage>248</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">12557293</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.schulze.2001.413">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schulze</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ebinger</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rating</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayatepek</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Improving treatment of guanidinoacetate methyltransferase deficiency: reduction of guanidinoacetic acid in body fluids by arginine restriction and ornithine supplementation.</article-title>
                <source>Mol Genet Metab</source>
                <volume>74</volume>
                <fpage>413</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11749046</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.schulze.2006.719">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schulze</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bachert</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kirsch</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verhoeven</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayatepek</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Presymptomatic treatment of neonatal guanidinoacetate methyltransferase deficiency.</article-title>
                <source>Neurology</source>
                <volume>67</volume>
                <fpage>719</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">16924036</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.schulze.1998.606">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schulze</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayatepek</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bachert</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marescau</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Deyn</surname>
                    <given-names>PP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rating</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Therapeutic trial of arginine restriction in creatine deficiency syndrome.</article-title>
                <source>Eur J Pediatr</source>
                <volume>157</volume>
                <fpage>606</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">9686828</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.sempere.2009a.745">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sempere</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fons</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arias</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodr&#x000ed;guez-Pombo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merinero</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alcaide</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Capdevila</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribes</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duque</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eir&#x000ed;s</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fern&#x000e1;ndez-Alvarez</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campistol</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Artuch</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2009a</year>
                <article-title>Cerebral creatine deficiency: first Spanish patients harbouring mutations in GAMT gene.</article-title>
                <source>Med Clin (Barc)</source>
                <volume>133</volume>
                <fpage>745</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">19892372</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.sempere.2009b.s91">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sempere</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fons</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arias</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodr&#x000ed;guez-Pombo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colomer</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merinero</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alcaide</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Capdevila</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribes</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Artuch</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campistol</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2009b</year>
                <article-title>Creatine transporter deficiency in two adult patients with static encephalopathy.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>32</volume>
                <supplement>Suppl 1</supplement>
                <fpage>S91</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">19319661</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.st_ckler.1996.914">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>St&#x000f6;ckler</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Isbrandt</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanefeld</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>von Figura</surname>
                    <given-names>K.</given-names>
                  </name>
                </person-group>
                <article-title>Guanidinoacetate methyltransferase deficiency: the first inborn error of creatine metabolism in man.</article-title>
                <source>Am J Hum Genet.</source>
                <year>1996</year>
                <volume>58</volume>
                <fpage>914</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">8651275</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.stockleripsiroglu.2012">
              <mixed-citation publication-type="book">Stockler-Ipsiroglu S, Mercimek-Mahmutoglu S, Salomons G. Creatine deficiency syndromes. In: Saudubray JM, van den Berghe G, Walter JH, eds. <italic toggle="yes">Inborn Metabolic Diseases. Diagnosis and Treatment.</italic> 5 ed. Springer-Verlag; 2012:239-47.</mixed-citation>
            </ref>
            <ref id="creatine.REF.stockleripsiroglu.2014.16">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stockler-Ipsiroglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Karnebeek</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longo</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korenke</surname>
                    <given-names>GC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mercimek-Mahmutoglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marquart</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barshop</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grolik</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlune</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angle</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ara&#x000fa;jo</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coskun</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Diogo</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geraghty</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haliloglu</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Konstantopoulou</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leuzzi</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levtova</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mackenzie</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maranda</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mhanni</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitchell</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morris</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newlove</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renaud</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scaglia</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valayannopoulos</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Spronsen</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verbruggen</surname>
                    <given-names>KT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yuskiv</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Nyhan, Schulze A. Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2014</year>
                <volume>111</volume>
                <fpage>16</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">24268530</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.trotierfaurion.2015.185">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Trotier-Faurion</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Passirani</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000e9;jaud</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x000e9;zard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valayannopoulos</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taran</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Lonlay</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benoit</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mabondzo</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2015</year>
                <article-title>Dodecyl creatine ester and lipid nanocapsule: a double strategy for the treatment of creatine transporter deficiency.</article-title>
                <source>Nanomedicine (Lond)</source>
                <volume>10</volume>
                <fpage>185</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">24559037</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.valayannopoulos.2012.151">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Valayannopoulos</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boddaert</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chabli</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barbier</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desguerre</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Philippe</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Afenjar</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazzuca</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheillan</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Keyzer</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Lonlay</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Treatment by oral creatine, L-arginine and L-glycine in six severely affected patients with creatine transporter defect.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>35</volume>
                <fpage>151</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">21660517</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.van_de_kamp.2011.264">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van de Kamp</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancini</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pouwels</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Betsalel</surname>
                    <given-names>OT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Dooren</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Koning</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steenweg</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Knaap</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Clinical features and X-inactivation in females heterozygous for creatine transporter defect.</article-title>
                <source>Clin Genet.</source>
                <volume>79</volume>
                <fpage>264</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">20528887</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.van_de_kamp.2012.141">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van de Kamp</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pouwels</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aarsen</surname>
                    <given-names>FK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ten Hoopen</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knol</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Klerk</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Coo</surname>
                    <given-names>IF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huijmans</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Knaap</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancini</surname>
                    <given-names>GM</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Long-term follow-up and treatment in nine boys with X-linked creatine transporter defect.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>35</volume>
                <fpage>141</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">21556832</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.van_de_kamp.2013a.463">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van de Kamp</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Betsalel</surname>
                    <given-names>OT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mercimek-Mahmutoglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdulhoul</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grunewald</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anselm</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Azzouz</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bratkovic</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Brouwer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamel</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleefstra</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yntema</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campistol</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vilaseca</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheillan</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Hooghe</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Diogo</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valongo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fonseca</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frints</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilcken</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>von der Haar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meijers-Heijboer</surname>
                    <given-names>HE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hofstede</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kant</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lion-Francois</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pitelet</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longo</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maat-Kievit</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monteiro</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntau</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nassogne</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osaka</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ounap</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pinard</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quijano-Roy</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poggenburg</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poplawski</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdul-Rahman</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribes</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arias</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yaplito-Lee</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schulze</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwenger</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soares</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sznajer</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valayannopoulos</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Esch</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waltz</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wamelink</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pouwels</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Errami</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Knaap</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancini</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                </person-group>
                <year>2013a</year>
                <article-title>Phenotype and genotype in 101 males with X-linked creatine transporter deficiency.</article-title>
                <source>J Med Genet</source>
                <volume>50</volume>
                <fpage>463</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">23644449</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.van_de_kamp.2013b.155">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van de Kamp</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gibson</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                </person-group>
                <article-title>New insights into creatine transporter deficiency: the importance of recycling creatine in the brain.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2013b</year>
                <volume>36</volume>
                <fpage>155</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">22968583</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.van_de_kamp.2014.715">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van de Kamp</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancini</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>X-linked creatine transporter deficiency: clinical aspects and pathophysiology.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>37</volume>
                <fpage>715</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">24789340</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.van_de_kamp.2015.141">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van de Kamp</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Errami</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Howidi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anselm</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winter</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phalin-Roque</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osaka</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Dooren</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancini</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinberg</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                </person-group>
                <year>2015</year>
                <article-title>Genotype-phenotype correlation of contiguous gene deletions of SLC6A8, BCAP31 and ABCD1.</article-title>
                <source>Clin Genet.</source>
                <volume>87</volume>
                <fpage>141</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">24597975</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.van_spronsen.2006.274">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Spronsen</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reijngoud</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verhoeven</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soorani-Lunsing</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sijens</surname>
                    <given-names>PE</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>High cerebral guanidinoacetate and variable creatine concentrations in argininosuccinate synthetase and lyase deficiency: implications for treatment.</article-title>
                <source>Mol Genet Metab</source>
                <volume>89</volume>
                <fpage>274</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16580861</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.velichkova.2006.16">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Velichkova</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Himo</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Theoretical study of the methyl transfer in guanidinoacetate methyltransferase.</article-title>
                <source>J Phys Chem B.</source>
                <year>2006</year>
                <volume>110</volume>
                <fpage>16</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16471489</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.verbruggen.2007.921">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Verbruggen</surname>
                    <given-names>KT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knijff</surname>
                    <given-names>WA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soorani-Lunsing</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sijens</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verhoeven</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goorhuis-Brouwer</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Spronsen</surname>
                    <given-names>FJ</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Global developmental delay in guanidinoacetate methyltransferase deficiency: differences in formal testing and clinical observation.</article-title>
                <source>Eur J Pediatr.</source>
                <volume>166</volume>
                <fpage>921</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">17186272</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.verhoeven.2004.441">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Verhoeven</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roos</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Struys</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Knaap</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Enzyme assay for diagnosis of guanidinoacetate methyltransferase deficiency.</article-title>
                <source>Clin Chem</source>
                <volume>50</volume>
                <fpage>441</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">14752017</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.verhoeven.2003.803">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Verhoeven</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schor</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roos</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Battini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stockler-Ipsiroglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Diagnostic enzyme assay that uses stable-isotope-labeled substrates to detect L-arginine:glycine amidinotransferase deficiency.</article-title>
                <source>Clin Chem</source>
                <volume>49</volume>
                <fpage>803</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">12709373</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.verma.2010.186">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Verma</surname>
                    <given-names>A.</given-names>
                  </name>
                </person-group>
                <article-title>Arginine:glycine amidinotransferase deficiency: a treatable metabolic encephalomyopathy.</article-title>
                <source>Neurology.</source>
                <year>2010</year>
                <volume>75</volume>
                <fpage>186</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">20625172</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.pasquali.2014.231">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pasquali</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwarz</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jensen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yuzyuk</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DeBiase</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Randall</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longo</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Feasibility of newborn screening for guanidinoacetate methyltransferase (GAMT) deficiency.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2014</year>
                <volume>37</volume>
                <fpage>231</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">24276113</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.viau.2013.255">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Viau</surname>
                    <given-names>KS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ernst</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasquali</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Botto</surname>
                    <given-names>LD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hedlund</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longo</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Evidence-based treatment of guanidinoacetate methyltransferase (GAMT) deficiency.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2013</year>
                <volume>110</volume>
                <fpage>255</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">24071436</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.vodopiutz.2007.773">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vodopiutz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Item</surname>
                    <given-names>CB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>H&#x000e4;usler</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korall</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bodamer</surname>
                    <given-names>OA</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Severe speech delay as the presenting symptom of guanidinoacetate methyltransferase deficiency.</article-title>
                <source>J Child Neurol.</source>
                <volume>22</volume>
                <fpage>773</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">17641269</pub-id>
              </element-citation>
            </ref>
            <ref id="creatine.REF.wyss.2000.1107">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wyss</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaddurah-Daouk</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>Creatine and creatinine metabolism.</article-title>
                <source>Physiol Rev.</source>
                <year>2000</year>
                <volume>80</volume>
                <fpage>1107</fpage>
                <lpage>213</lpage>
                <pub-id pub-id-type="pmid">10893433</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="creatine.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="creatine.Suggested_Reading.reflist0">
            <ref id="creatine.REF.von_figura">
              <mixed-citation publication-type="book">von Figura K, Hanefeld F, Isbrandt D, St&#x000f6;ckler-Ipsiroglu S. Guanidinoacetate methyltransferase deficiency. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID)</italic>. Chap 84. New York, NY: McGraw-Hill. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/">online</ext-link>.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="creatine.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="creatine.Author_History">
          <title>Author History</title>
          <p>Saadet Mercimek-Mahmutoglu, MD, PhD, FCCMG (2008-present)Gaija S Salomons, PhD (2008-present)Sylvia St&#x000f6;ckler-Ipsiroglu, MD, PhD, MBA, FRCPC; University of British Columbia (2008-2015)</p>
        </sec>
        <sec id="creatine.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>10 December 2015 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>18 August 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>15 January 2009 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>24 July 2008 (smm) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="creatine.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Algorithm for diagnosis of the cerebral creatine deficiency syndromes. Note: Urinary creatine/creatinine ratio and creatine uptake studies in cultured skin fibroblasts are often not informative in females with SLC6A8 deficiency; hence, molecular genetic testing is the preferred method of diagnosis of females with this disorder [<xref ref-type="bibr" rid="creatine.REF.van_de_kamp.2011.264">van de Kamp et al 2011</xref>].</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="creatine-Image001" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="creatine.F2" orientation="portrait">
          <label>Figure 2. </label>
          <caption>
            <p>Schema illustrating (1) CREATINE SYNTHESIS that occurs mainly in liver, pancreas, and kidney; (2) CREATINE UPTAKE into muscle and brain by the creatine transporter (CRTR); and (3) non-enzymatic conversion of creatine to creatinine for CREATININE EXCRETION in the urine</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="creatine-Image002" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
